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Abstract 
 
Beauvericin (BEA) and enniatins (ENN) are structurally related cyclohexadepsipeptides 
produced by Fusarium that are known to contaminate food and feed. There is 
compelling evidence that fungal toxins may influence development and activity of 
osteoclasts (OC) and consequently, may be useful for the treatment of osteoporosis and 
bone tumors. Thus, this study aimed to characterize pharmacological and toxicological 
activities of BEA and ENN on bone cells (osteoblasts and osteoclasts), as well as on 
metastatic (MDA-MB-231 and PC3) and non metastatic (U2OS) cancer cell lines. 
BEA inhibited bone resorption by disrupting the resorbing organelle (actin ring) of OC, 
while ENN did not affect the actin ring structure and inhibited bone resorption directly 
by reducing the number of TRAP-positive OC. Moreover, BEA did not affect cell 
viability of mature OC, but induced apoptosis in pre-fusion OC, likely by mechanisms 
involving ERK1/2 phosphorylation. Interestingly, ENN inhibited OC viability in a 
Src/Akt dependent manner and induced signal transduction pathways similar to PP2, a 
reference Src inhibitor. These data suggest that BEA and ENN differentially regulate 
OC life span and activity. 
Inhibition of cell growth, cell viability and induction of apoptosis was observed in 
MDA-MB-231, PC3 and U2OS. BEA and ENN similarly affected the metastatic 
(MDA-MB-231 and PC3) and non metastatic cell viability (U2OS), as early as 24 h, 
with a significant effect observed already at 5 µM drug. Both inhibitors more potently 
induced apoptosis after 24 h in metastatic cells compared to non metastatic, with ENN 
being more potent compared to BEA. We studied the signaling pathways leading to 
proliferation, survival, apoptosis and motility. Interestingly, the metastatic profile did 
not seem to confer any selective advantage for the effects of both inhibitors at the 
molecular level. Indeed, while the p38 MAPK pathway remained continuously activated 
in all cell lines, BEA and ENN inactivated ERK in MDA-MB-231 as opposed to its 
upregulation in PC3 and U2OS. Moreover, BEA was able to induce PARP cleavage in 
all cell lines, whereas ENN did so only in PC3. Finally, E-cadherin was upregulated in 
all cell lines following BEA or ENN treatment. 
These data demonstrate the antiresorptive and antitumoral activities of BEA and ENN, 
and their therapeutic potential in the treatment of OC-induced bone loss, bone cancer 
and skeletal metastases. 
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Kurzfassung 
 
Beauvericin (BEA) und Enniatine (ENN) sind strukturell verwandte, sekundäre 
Metabolite (Cyclohexadepsipeptide) von Fusarium und als Kontamination von 
Nahrungs-und Futtermitteln beschrieben. Basierend auf Publikationen, daß strukturell 
verwandte Mykotoxine die Differenzierung und Funktion von Osteoklasten 
beeinflussen können, stellte sich die Frage, ob diese Substanzklasse zur Behandlung 
von Knochenerkrankungen eingesetzt gezogen werden kann. Ziel dieser Arbeit war es 
daher, die pharmakologische und toxikologische Wirkung von BEA und ENN auf 
Knochenzellen - Osteoblasten und Osteoklasten- und Tumore, die selektiv in den 
Knochen metastasieren bzw. Knochentumore entwickeln, zu untersuchen. BEA hemmte 
die Knochenresorption durch eine Zerstörung des Resorptionsapparates des 
Osteoklasten, des Aktinrings. Im Gegensatz dazu beeinflußte ENN die Struktur des 
Aktinringes nicht und hemmte die Knochenresorption über eine Verminderung der 
Differenzierung von Vorstufen zu reifen Osteoklasten. BEA zeigte keinen toxischen 
Einfluss auf reife Osteoklasten, induzierte jedoch Apoptose bei Osteoklastenvorläufern 
über Mechanismen, die auf erhöhter Phosphorylierung von ERK1/2 basieren. Im 
Gegensatz dazu reduzierte ENN die Viabilität von Osteoklasten, dies erfolgte über 
einen Src/Akt-abhängigen Mechanismus, die ausgelösten Modulation der 
Signaltransduktionswege waren ähnlich der Wirkung von PP2, einem Standardinhibitor 
der Src-Kinase. BEA und ENN hemmen somit über unterschiedliche Mechanismen die 
Lebensspanne und Aktivität von Osteklasten. Anschließend wurde die Wirkung von 
BEA und ENN auf das Wachstum, Zellviabilität und Apoptoseinduktion von 
knochenspezifischen Tumortypen untersucht. BEA und ENN hemmten die Viabilität 
metastasierender Tumorzelllinien (MDA-MB-231 für Mamacarcinom und PC3 für 
Prostatacarcinom ) und nicht metastasierende Tumorzellen (U2OS) in der Konzentra-
tion von 5 µM bereits innerhalb von 24 h. Bei längerer Einwirkzeit war die Induktion 
der Apoptose bei metastasierenden Tumorzellen stärker als bei nicht metastasierenden 
Zellen, wobei ENN potenter als BEA war. Zur weiteren Charakterisierung wurde die 
Wirkung der beiden Mykotoxine auf die wichtigsten Signaltransduktionswege von 
Zellproliferation und Apoptose untersucht. Hier zeigte sich, daß der p38 MAPK-
Signaltransduktionsweg in allen Zelllinien aktiviert wurde, der ERK-Weg war in MDA-
MB-231 inaktiviert und in PC3- und U2OS-Zellen stimuliert. BEA stimulierte die 
Spaltung des Apoptosemarker-Enzyms bei allen Zelltypen, ENN hingegen nur bei PC3. 
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E-Cadherin, einem Marker für Zelladhäsion wurde in allen Zelllinien durch BEA und 
ENN stimuliert. 
In dieser Arbeit konnten die die antiresorptiven und antitumoralen Effekte von BEA 
und ENN beschrieben und charakterisiert werden, die Ergebnisse zeigen ihr Potential in 
der Therapie von osteolytischen Knochenerkrankungen, wie Osteoporose, sowie 
Knochentumore und -metastasen. 
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1 Introduction 
 
Osteoporosis is a progressive disease of bone; characterized by reduced bone mass, 
bone fragility, deterioration of bone microarchitecture leading to increase risk of 
fractures. It occurs when bone formation (by osteoblasts) and resorption (by osteoclasts) 
are not tightly coupled with regard to quantity, time and space (Zaidi, 2007). 
Osteoporosis is common in postmenopausal women (postmenopausal osteoporosis), but 
also occurs in men or can be induced by other disease states (cancer-induced 
osteoporosis) or some medications (glucocorticoid-induced osteoporosis). We review in 
this section the physiology of the cells responsible for growth and maintenance of bone 
(osteoblasts and osteoclasts), as well as the mechanisms of bone metastases, particularly 
from breast and prostate cancer. Moreover, we review the knowledge about 
cyclodepsipeptides (particularly beauvericin and enniatins), mycotoxins used in the 
framework of this study to characterize their roles in bone cells and bone metastases. 
 
1.1 Bone cells 
 
Bone is a highly specialized type of connective tissue, which provides structural 
support, protective and mechanical functions and plays a critical role in mineral 
homeostasis. Bones of the body are either long (tibia, femur and humerus) or flat (skull, 
ileum and mandible); both of which contain cortical and trabecular bone albeit in 
different concentrations (Bussard et al., 2008). Cortical bone, mainly present in long 
bone shafts is the compact, dense outer protective layer of mineralized hardened 
collagen that provides mechanical strength and support to the body. Trabecular or 
cancellous bone in contrast is predominant in the axial skeleton and at the ends of long 
bones, has a loosely organized porous matrix and exhibits a greater turnover rate than 
cortical bone. 
The skeleton is made up of three specific cell types, namely the chondrocytes in 
cartilage, and the osteoblasts and osteoclasts in bone (Karsenty, 2001). For the purpose 
of this review, our attention will be focused on bone cells. 
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1.1.1 Osteoblasts 
 
1.1.1.1 Definition 
 
Osteoblasts are mononucleated cells of mesenchymal origin that are responsible for 
bone formation. Under light microscopy, they appear as plump cells, approximately 20-
30 µm in diameter, lined up on the surface of unmineralized osteoid (Milat and Ng, 
2009). Active osteoblasts synthesize and stain positive for alkaline phosphatase, a 
useful marker for the detection of osteoblasts in culture. After secretion of matrix 
proteins, the osteoblast loses its synthetic capacity and either becomes a lining cell 
(resting osteoblast with flat-elongated morphology that lines cancellous and 
endocortical bone surfaces), or becomes trapped behind an advancing calcification front 
where it is embedded in bone lacunae as an osteocyte. Lining cells regulate the passage 
of calcium into and out of the bone, and respond to hormones by making special 
proteins that activate osteoclasts. 
 
1.1.1.2 Role 
 
Osteoblasts secrete unmineralized material called osteoid, mainly composed of fibers 
(type I collagen) and non-collagenous components (chondroitin sulfate, osteocalcin, 
osteonectin, bone sialoprotein and proteoglycans). Moreover, they are responsible for 
mineralization of this osteoid matrix, a well-orchestrated process in which crystals of 
calcium phosphate in the form of hydroxyapatite [3Ca(PO4)2(OH)2] are produced and 
laid down in precise amounts in the organic matrix. Mineralization is critical as it 
provides hardness and strength, preventing bones from inadvertently bending when a 
force is applied. Osteoblasts play a crucial role in osteoclast differentiation and bone 
resorption through their expression of key cytokines, the most important of which 
include the macrophage colony stimulating factor (M-CSF), the receptor activator of 
NFκB ligand (RANKL) and osteoprotegerin (OPG), a decoy RANK receptor that 
inhibits bone resorption (Suda, et al., 1999). 
 
1.1.1.3 Transcriptional regulation of osteogenesis  
 
Osteoblasts arise from mesenchymal progenitors cells in the periosteum and the bone 
marrow. Very few bones, in particular the clavicles and some flat bones of the skull, 
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develop without a cartilage template, in a process called intramembranous ossification 
(Hill, et al., 2005). However, in all the other bones, differentiation of mesenchymal cells 
into proliferating chondrocytes precedes osteoblast differentiation in a three key steps 
process of endochondral ossification (Karsenty, 2001): (1) mesenchymal condensation, 
proliferation of chondrocytes and differentiation into hypertrophic chondrocytes; (2) 
vascular invasion from the perichondrium or bone collar along with invasion of 
mesenchymal progenitors (3) that will differentiate into osteoblasts. This highlights the 
interdependence between chondrocyte hypertrophy and osteoblast differentiation for 
bone formation to occur (Figure 1). 
 
Figure 1. Regulation of chondrocyte and osteoblast differentiation (Kobayashi and 
Kronenberg, 2005) 
 
Bone morphogenic proteins (BMPs) are the only factors capable of initiating 
osteoblastogenesis from uncommitted precursors. They induce mesenchymal 
condensation upon binding to their receptors (BMP receptors type I and II) by 
phosphorylating their downstream target Smads (1, 5 and 8) (Miyazawa, et al., 2002). 
Chondrogenesis is mediated by BMPs-dependent expression of Sox9, a high-mobility-
group (HMG) domain transcription factor required for chondrocyte lineage commitment 
(Kobayashi and Kronenberg, 2005). Sox9 plays essential roles in successive steps of 
chondrocyte differentiation, including mesenchymal condensation, conversion of 
mesenchymal cells into chondrocytes, proliferation of chondrocytes, and prevents 
proliferating chondrocytes to differentiate into hypertrophic chondrocytes (Akiyama, et 
al., 2002; Bi, et al., 1999). Moreover, Sox9 is required for the expression of its two 
related family members, L-Sox5 and Sox6, both of which are important for normal 
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chondrocyte function (Smits, et al., 2001). Other signaling molecules such as Indian 
hedgehog (Ihh), Wnts, ß-catenin, TCf/LEF complex have also been shown to regulate 
chondrogenesis (Hartmann and Tabin, 2000; St-Jacques, et al., 1999) although 
individual or combined effects, as well as their molecular mechanism are partially 
appreciated. 
Chondrocyte hypertrophy is a mandatory step during endochondral ossification. Yet, the 
Cbfa1 transcription factor (or Runx2), one of the mouse homologs of the drosophila 
runt protein, is induced by BMPs, expressed early in development (embryonic day 12) 
in chondro-osteoprogenitors present in mesenchymal condensations of the developing 
skeleton (Ducy, et al., 1997), and acts as the hypertrophic chondrocyte differentiation 
factor (Inada, et al., 1999; Takeda, et al., 2001). Runx2 and Runx3 are essential for 
chondrocyte maturation and Runx2 regulates limb growth by organizing chondrocyte 
maturation and proliferation through the induction of Indian hedgehog (Ihh) expression 
(Yoshida, et al., 2004). From embryonic day 14, Cbfa1 (or Runx2) expression gradually 
fades away in the cells of the chondrocyte lineage while it strongly increases in the cells 
of the osteoblast lineage and constitutes the most specific and earliest commitment 
marker of the osteoblast lineage (Ducy, et al., 1997). 
Runx2 is absolutely required for differentiation to proceed to the osteoblast and to no 
other lineage (Karsenty, 2001; Kobayashi and Kronenberg, 2005). Runx2 can be 
activated downstream of smads, or directly following phosphorylation by PTH and 
FGFs (Zaidi, 2007). Interestingly, Runx2 oeteogenic activity is suppressed by 
interaction of its DNA binding domain with the Twist box domain of Twist 
transcription factors (Bialek, et al., 2004). Runx2 binds to the cis-acting elements of 
osteoblast specific genes, including type I collagen, bone sialoprotein, osteopontin, 
osteocalcin, and regulate their expression (Ducy and Karsenty, 1995). 
Osterix (Osx) is another obligatory signal for osteoblastogenesis, as Osx-deficient mice, 
similarly to Runx-/-, do not deposit bone (Nakashima, et al., 2002). However, Osx null 
mice, unlike Runx2-/-, express normal Runx2 levels indicating that Osx acts 
downstream of Runx2. NFAT2 (Nuclear factor of activated T cells 2) is important for 
the transcriptional activity of Osx (but not Runx2), as the two of them form a complex 
that bind to DNA and regulates expression of target genes (Koga, et al., 2005). 
Canonical Wnt/ß-catenin signaling is another critical pathway in osteoblastogenesis 
(Milat and Ng, 2009; Westendorf, et al., 2004). Wnt family members are secreted 
glycoproteins, defined by sequence homology to drosophila wingless (wg) and the 
murine int-1 protooncogene. Canonical Wnts (including Wnt4, Wnt5a and Wnt11) 
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interact with their receptors of the Frizzled family and co-receptors of the LRP5/6 
family to stabilize cytoplasmic ß-catenin. Stabilization of ß-catenin occurs through its 
phosphorylation by the glycogen synthase kinase-3ß (GSK3), its translocation to the 
nucleus where it binds to transcription factors such as T cell specific transcription 
factor/Lymphoid enhancer binding factor (TCF/LEF) to regulate transcription of target 
genes. Consistent with the role of Wnt/ß-catenin in skeletogenesis is the realization that 
antagonists of Wnt signaling, including Dickkopfs proteins (compete with Wnts for 
binding to the LRP5/6 receptor), secreted frizzled related proteins and Wnt inhibitory 
factor 1 (bind directly to Wnts), and sclerostin (product of SOST gene that binds on the 
LRP5/6 receptor) lead to decreased bone formation and bone mass. Moreover, canonical 
Wnt/ß-catenin signaling controls a molecular switch that regulates lineage commitment 
between chondrocytes and osteoblasts, preventing transdifferentiation of osteoblastic 
cells into chondrocytes (Hill, et al., 2005). There are now clear evidence of interaction 
between the signaling pathways linked to PTH, BMPs and LRP/Wnt actions leading to 
bone formation, although data are insufficient to appreciate the relative contribution of 
each of these pathways (Milat and Ng, 2009). 
 
1.1.1.4 Osteocytes 
 
Osteocytes are retired osteoblasts trapped in the bone lacunae, and represent the most 
abundant cell type in bone (about ten times more than osteoblasts). They have a star-
shaped like morphology and communicate with each other and with other cells via long 
cytoplasmic extensions that run along tiny canals called canaliculi. Osteocytes do not 
express alkaline phosphatase, but act as mechanosensors as they sense and respond to 
changes in fluid flow arising from stress, strain or pressure (Han, et al., 2004). They 
negatively regulate bone formation through their secretion of sclerostin. Sclerostin is the 
product of the SOT gene that acts as a master regulatory break molecule on bone 
formation. In line with this are the observations that loss of function mutations result in 
high bone mass phenotypes (Balemans, et al., 2001; Brunkow, et al., 2001; Loots, et al., 
2005). Sclerostin antagonizes the Wnt/ß-canonical signaling by binding to the 
extracellular domain of the Wnt co-receptors LRP5 and LRP6, and by disrupting Wnt-
induced Frizzled /LRP complex formation (Semenov, et al., 2005). 
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1.1.1.5 Regulation of osteoblast apoptosis 
 
Apoptosis or programmed cell death, with typical apoptotic features of condensed 
chromatin and/or nuclear fragmentation, appears less frequently in osteoblasts in vivo as 
compared to osteoclasts (Xing and Boyce, 2005). However, increased osteoblast 
apoptosis is generally mirrored by decreased bone formation. Human postmenopausal 
osteoblasts constitutively express Fas receptors, which upon activation by their ligand 
Fas, induce cell death (Garcia-Moreno, et al., 2004). Osteoblasts do also express 
functional death receptors for TNF and TRAIL (TNF related apoptosis inducing ligand). 
Mechanistically (Xing and Boyce, 2005), these death receptors (CD95 for FasL and 
DR5 for TNF and TRAIL) contain an intracellular death domain that upon activation of 
the receptor recruits adaptor proteins, such as FADD (Fas-associated death domain) or 
TRADD (TNF related associated death domain). These adaptor proteins themselves 
bear a death effector domain (DED) that recruits DED-containing proteins such as 
procaspase-8. Apoptosis can also be induced by the classical mitochondrial pathway 
regulated by Bcl-2 family proteins, which involves mitochondrial release of cytochrome 
c and activation of initiator and executor caspases leading to cleavage of life essential 
proteins. Some factors including intermittent PTH, IGFs, FGF, TGFß, sex steroids 
(estrogen and testosterone), IL-6 and leptin exert antiapoptotic effects on osteoblasts. 
Interestingly, BMP-2, a member of the TGFß family that regulates osteoblast 
differentiation and bone formation has a novel function of promoting osteoblast 
apoptosis through a Smad-independent, protein kinase C dependent signaling pathway 
resulting in cytochrome c release from the mitochondria and activation of caspase 9, 3, 
6 and 7 (Hay, et al., 2001). Glucocorticoid therapy leads to bone loss due to impaired 
intestinal calcium absorption, decreased osteoblastogenesis, increased osteoclast activity 
and/or life span, and increased apoptosis of osteoblasts and osteocytes (Xing and Boyce, 
2005). 
 
1.1.2 Osteoclasts 
 
1.1.2.1 Definition and role 
 
Osteoclasts are large, terminally differentiated multinucleated cells highly specialized in 
breaking down the mineralized bone matrix. They are located on bone surfaces in the 
so-called Howship’s lacunae or resorption pits. The average osteoclast bears about 5 to 
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20 nuclei, although osteoclasts with up to 200 nuclei may exist. Their cytoplasm 
appears homogeneous and foamy in regard to their high concentration of vesicles and 
vacuoles. They express high levels of Tartrate Resistant Acid Phosphatase (TRAP) and 
can therefore be identified in culture by staining of this enzyme. 
Morphological and functional features of an active osteoclast include adherence to the 
bone surface, the ability to migrate efficiently toward and along bone surfaces, synthesis 
and directional secretion of hydrolytic enzymes, acidification of the subosteoclastic 
bone resorbing compartment and efficient internalization of extracellular bone matrix 
degradation products (Bruzzaniti and Baron, 2006). At a site of active bone resorption, 
the osteoclast forms a specialized apical cell membrane, the ruffled border, which 
faces the bone surface and acts as the main resorptive organelle. Another critical 
component at this apical membrane is the sealing zone, an actin reach area surrounding 
the ruffled border that closely interact with the bone matrix, thus sealing off the 
subosteoclastic bone-resorbing compartment. 
 
1.1.2.2 Osteoclastogenic cytokines 
 
RANKL is the key osteoclastogenic cytokine expressed by osteoblasts/stromal cells 
(Yasuda, et al., 1998). However, RANKL is also expressed in high levels in antigen 
activated T cells and plays a critical role in the pathogenesis of rheumatoid arthritis-
induced bone loss (Kong, et al., 1999). Actually, TNFα is the key cytokine mediating 
the periarticular bone loss of rheumatoid arthritis, promoting osteoclast formation and 
activation in inflamed joint by stimulating RANKL production by marrow stromal cells, 
and by directly stimulating differentiation of osteoclasts precursors (Teitelbaum, 2007). 
TNFα is pivotal to the pathogenesis of inflammatory osteolysis and acts synergistically 
with RANKL. However, whether TNFα alone can induce osteoclast differentiation is 
still debatable. Indeed, Lam and colleagues (Lam, et al., 2000) reported that TNFα is 
incapable of inducing osteoclastogenesis in vitro and in vivo unless attended by 
permissive levels of RANKL while Kim and colleagues (Kim, et al., 2005) claimed that 
the inflammatory cytokine is sufficient to induce osteoclastogenesis in the absence of 
RANK signaling in vitro if attended by TGFß. IL-1 is able to induce RANKL 
expression by stromal cells and directly stimulates osteoclast precursor differentiation in 
a p38 MAPK-dependent manner (Wei, et al., 2005). Moreover, IL-1 mediates the 
osteoclastogenic effect of TNFα and directly promotes the osteoclast phenotype 
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independently of TNFα in the presence of permissive levels of RANKL (Wei, et al., 
2005). M-CSF, also produced by marrow stromal cells is required for macrophage 
survival and proliferation and more importantly, plays a crucial role in osteoclast 
differentiation. This fit well with the observation that op/op mice, which lack functional 
M-CSF, have osteoclast-deficient osteopetrosis (Yoshida, et al., 1990). M-CSF and 
RANKL are sufficient for osteoclastogenesis, as pure populations of osteoclasts can be 
generated in vitro by cultivating marrow macrophages in the sole presence of these 2 
cytokines. RANKL activity is negatively regulated by OPG, a glycoprotein molecule 
produced by osteoblasts that competes with RANK as a soluble decoy receptor 
(Simonet, et al., 1997). 
 
1.1.2.3 Regulation of osteoclastogenesis 
 
Osteoclasts originate from multipotent hematopoietic stem cells in the bone marrow 
(Coccia, et al., 1980; Udagawa, et al., 1990). The earliest known event in 
osteoclastogenesis is determination of the stem cell precursor (Figure 2), and is induced 
by the B-cell transcription modulator PU.1 (Tondravi, et al., 1997). At around this 
point, the cells acquire the c-fms receptor and start to proliferate in response to 
stimulation of that receptor by M-CSF, a cytokine produced by nearby stromal cells. 
Consistent with the role of M-CSF in osteoclastogenesis, op/op mice defective in the 
production of functional M-CSF are severely deficient in mature macrophages and 
osteoclasts (Yoshida, et al., 1990). Up to this point, B-lymphocytes can still be formed, 
but the appearance of c-fos and RANK receptor fully commit precursors to an osteoclast 
lineage (Zaidi, 2007). It is important to point here that RANK receptor is as well 
expressed on chondrocytes, dendritic cells and mature osteoclasts (Kong, et al., 1999). 
Another critical cytokine required for osteoclastogenesis is RANKL, a member of the 
TNF family, also released by nearby stromal cells. RANKL, a membrane-residing 
protein on stromal cells binds to its receptor RANK on macrophages and trigger signal 
transduction cascades leading to the expression of differentiation and survival genes; 
thus, a genetic defect of any molecule downstream of RANK results in arrest of 
osteoclastogenesis. Mechanistically (Zaidi, 2007), upon activation, RANK recruits the 
docking protein TRAF6 (TNF receptor associated factor 6) to its cytoplasmic domain to 
activate NFκB and all three families of MAP kinases (JNK, ERK1/2 and p38). In line 
with this is the observation that mice lacking the p50 and p52 subunits of NFκB fail to 
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generate osteoclasts and are osteopetrotic (Franzoso, et al., 1997). RANKL-induced 
MAP kinase signaling leads to the activation of AP-1 (activator protein 1), a dimeric 
complex mainly composed of FOS and JUN. In parallel, the transcription factor 
NFATc1 (Nuclear factor of activated T cell 1) is activated by the calcium/calmodulin-
regulated phosphatase calcineurin; is translocated to the nucleus where it binds 
consensus sequence on DNA; and together with c-fos, amplifies key osteoclast genes 
including NFATc1 itself. 
 
Figure 2. Regulation of osteoclastogenesis (Aubin and Bonnelye, 2000) 
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c-fos (major component of AP-1) is important for osteoclastogenesis, as c-fos-/- mice 
lack osteoclasts and are osteopetrotic (Johnson, et al., 1992; Wang, et al., 1992). 
However, the effects of c-fos are thought to be mediated by NFATc1, as the latter is 
able to rescue osteoclastogenesis in c-fos-/- precursors (Matsuo, et al., 2004). So 
NFATc1, the most distal effector, is not only indispensable, but also sufficient for 
osteoclastogenesis, as its overexpression yields osteoclasts even in the absence of 
RANKL (Zaidi, 2007). 
Microphtalmia-associated transcription factor (Mitf) and Tfe3, both members of the 
basic/helix-loop-helix/leucine zipper (b-HLH-ZIP) transcription factor subfamily MiT, 
reside furthest along in the differentiation process and are essential for differentiation of 
mononuclear precursors (pre-fusion osteoclasts) into multinucleated osteoclasts 
(Hershey and Fisher, 2004). They directly regulate genes important for osteoclast 
function such as TRAP, cathepsin K, OSCAR (osteoclast-associated receptor); and may 
also regulate other transcription factors essential for osteoclastogenesis such as PU.1 
and c-Fos by physical interaction (Kobayashi and Kronenberg, 2005). 
 
1.1.2.4 Regulation of bone resorption 
 
Bone is a very dynamic tissue, which is continuously being resorbed and rebuilt. 
Remodeling is essential in normal physiologic conditions to regulate calcium 
homeostasis, to repair micro-damaged bone, as well as to shape and sculpture the 
skeleton during growth. The osteoclast is unique in its ability to do that job. 
Accordingly, the mature osteoclast must undergo some morphological changes to 
acquire specific features of an “activated” bone resorbing cell. 
At first, the osteoclast attaches to the bone matrix via its vitronectin αvß3 receptor with 
RGD (Arg-Gly-Asp) motifs of matrix proteins. This triggers an “outside-in” signaling 
characterized by the recruitment of Src at the cell membrane and the tyrosine 
phosphorylation of a distinct set of proteins, including Pyk2, Cbl, paxillin, cortactin, 
vinculin, talin, tensin and p130cas (Bruzzaniti and Baron, 2006). This αvß3-dependent 
signaling leads to the formation of complexes that include c-Src, Syk and the Rac-
specific guanine nucleotide exchange factor vav-3, and causes adhesion (sealing zone). 
Once adherent, the osteoclast polarizes (Zaidi, 2007): its bone-apposed ventral 
membrane invaginates into complex folds to form the ruffled border, the main 
resorptive organelle. Therefore, the “activated” osteoclast creates an isolated 
microenvironment between itself and the bone matrix by displaying an apical domain 
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against the bone surface, carrying secretory (ions and lysozomal enzymes by 
exocytosis) and absorptive (bone matrix degradation products by endocytosis) 
functions; and a basolateral domain away from the bone surface, through which cell 
matrix degraded products are excreted (Bruzzaniti and Baron, 2006). 
Protons are synthesized by carbonic anhydrase II (CO2 + H20 → HCO3- + H+), packed 
in Vacuolar ATP-ases vesicles, transported probably via microtubules and inserted into 
the ruffled border. These protons are then pumped out in the isolated microenvironment 
and the resulting acidification mobilizes the mineral phase out of the matrix. To prevent 
intracellular alkalinization that would otherwise occur, this proton secretion is counter-
balanced by parallel extrusion of chloride ions through the CIC-7 chloride channel 
(Teitelbaum, 2007). Chloride ions enter the cell at the basolateral membrane exchanging 
with bicarbonate (bicarbonate/chloride exchangers), are packed as well in vesicles, 
transported and released through the ruffled border via the CIC-7 channel in the bone 
lacunae where they charge-coupled to protons into HCl, bringing the ambient pH to fall 
to an approximate value of 4.5 (Schlesinger, et al., 1997). This allows acid-optimal 
lysozomal enzymes such as cathepsin K (released in the bone lacunae) to break down 
the helical and telopeptides regions of the organic matrix (collagen). Some of these 
organic and inorganic degradation products are endocytosed in the osteoclast; some are 
degraded within secondary lysosomes while others are transported through the cell by 
transcytosis and excreted through the basolateral domain. 
Hydroxyapatite dissolution elevates the ambient Ca2+ that in turn activates a Ca2+ sensor 
on the osteoclast surface, causing the rapid release of Ca2+ from intracellular stores. 
This rising cytosolic Ca2+ acts negatively on resorption, signaling the osteoclast to 
detach and retract from the bone surface (Zaidi, 2007). The osteoclast then loses the 
cytoskeletal features characteristic of activation and migrates to the next point on the 
bone to start anew the cycle (attachment-resorption-migration). With each cycle, the 
osteoclast leaves on the bone surface a characteristic mark, the so-called “resorption pit” 
that can be observed as purple lighting spots under the microscope after in vitro staining 
with toluidine blue. Degraded bone matrix products remaining at the site of resorption 
following osteoclast migration may play a role in the coupling of bone resorption with 
bone formation during the skeletal remodeling sequence (Bruzzaniti and Baron, 2006).  
Bone remodeling appears as a highly coordinated and structured process, where the 
components perfectly interact with each other. Therefore, any defect in each of the 
signaling component namely, the vacuolar proton pump V-ATPase (Frattini, et al., 
2000; Kornak, et al., 2000; Scimeca, et al., 2000), the chloride channel CIC-7 (Kornak, 
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et al., 2001), carbonic anhydrase II (Sly, et al., 1983) or cathepsin K (Gelb, et al., 1996) 
results in altered bone resorption and osteopetrosis. The same holds for Src, Syk and 
pyk2 (Bruzzaniti and Baron, 2006). 
 
1.1.2.5 Regulation of osteoclast apoptosis 
 
After bone breakdown, the osteoclast undergoes apoptosis. Morphological changes 
characteristic of osteoclast apoptosis include cell shrinking, chromatin condensation, 
nuclear fragmentation and strong TRAP staining (Xing and Boyce, 2005). Decreased 
osteoclast apoptosis usually correlates with increased bone loss as observed in 
rheumatoid arthritis and glucocorticoid-induced osteoporosis. Although TNFα can 
induce programmed cell death in a number of cell types upon binding to its death 
receptor DR5 (Xing and Boyce, 2005), increasing evidence support its role in 
promoting osteoclast survival rather than death. Indeed, TNFα has been shown to 
suppress apoptosis in osteoclasts through another signaling pathway involving the 
activation of the transcription factor NFκB (Van Antwerp, et al., 1996). The anti 
apoptotic protein Bcl-xL is expressed in osteoclast precursors and its expression is 
upregulated following treatment with M-CFS alone or in association with RANKL 
(Woo, et al., 2002). Nevertheless, RANKL alone is not sufficient to prevent apoptosis 
of osteoclasts precursors. Expression of a truncated Src molecule Src251, lacking the 
kinase domain induces apoptosis in osteoclasts associated with reduced Akt kinase 
activity, and provides evidence of a role of Src in osteoclast survival (Xing, et al., 
2001). Additionally, Src inhibitors induce osteoclast apoptosis through selective 
sustained ERK1/2 phosphorylation (Recchia, et al., 2004). Inhibition and activation 
studies of ERK and NFκB in osteoclasts using adenovirus vectors suggest a role of 
ERK, but not NFκB in osteoclast survival (Miyazaki, et al., 2000). PTH and 1,25(OH)2 
vitamin D3, like many other factors that stimulate bone resorption prevent osteoclast 
apoptosis, most likely by stimulating expression of RANKL and decreasing expression 
of OPG by stromal cells (Xing and Boyce, 2005). 
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1.1.3 Bone homeostasis 
 
1.1.3.1 Effect of parathyroid hormone and vitamin D3 
 
Calcium metabolism is the mechanism by which the body maintains adequate calcium 
levels. Calcium is the most abundant mineral in the human body. The average adult 
body contains in total approximately 1 kg, 99 % of which is stored in the skeleton in the 
form of hydroxyapatite crystals. Normal plasma concentration ranges between 2.2 to 2.6 
mmol/l and ionized calcium between 1.1 to 1.4 mmol/l. About 40 % of total blood 
calcium is bound to plasma proteins, primarily albumin. The remaining 60 % includes 
ionized calcium plus calcium complexed with phosphate (PO4) and citrate. The ionized 
or free calcium is the physiologically active form in the plasma and is the one 
commonly measured because of its clinical relevance. The regulation of calcium 
balance is greatly influenced by concentrations of circulating parathyroid hormone 
(PTH), 1,25-(OH)2-vitamin D3 and to a lesser extent calcitonin (Figure 3). 
 
 
Figure 3. Calcium metabolism 
 
PTH is secreted by parathyroid glands (located behind the thyroid gland) in response to 
low calcium levels and promotes release of calcium from the bone (thus stimulates bone 
resorption). PTH also increases plasma calcium by stimulating conversion of 25-OH-
vitamin D3 in the kidney in its most active form 1,25-(OH)2-vitamin D3. The latter then 
promotes dietary calcium intestinal absorption (by increasing the number of calcium 
binding proteins) and calcium resorption from the kidney. Despite increased calcium 
absorption, long-term increases in PTH secretion generally result in further bone 
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resorption by inhibiting osteoblastic function and promoting osteoclastic activity. PTH 
and vitamin D both function as important regulators of bone growth and bone 
remodeling. On the other hand, when plasma calcium levels are high, the thyroid 
parafollicular cells secrete calcitonin, which promotes cellular uptake, renal excretion 
and bone formation. Calcium metabolism disorders include hypocalcemia, 
hypercalcemia, osteomalacia and more importantly osteoporosis. 
 
1.1.3.2 Bone disorders 
 
1.1.3.2.1 Bone loss disorders 
 
Bone loss occurs when osteoclastic bone resorption exceeds osteoblastic bone 
formation. An absolute increase in the rate of bone resorption, with a relative, but 
insufficient increase in the rate of bone formation, leads to high turnover bone loss 
(Zaidi, 2007). This bone loss can be generalized (as observed in hypogonadism, 
thyrotoxicosis, hyperparathyroidism and disease of cytokine excess), or localized in 
focal osteolysis as observed in skeletal metastases, Paget’s bone disease, rheumatoid 
arthritis and periodontitis. Opposed to the hyper-resorption that defines high-turnover 
disorders, bone resorption can slow down per se and lag behind resorption, leading to 
low turnover osteoporosis, as is the case in aging, disuse, glucocorticoids and 
calcineurin inhibitors (Zaidi, 2007). 
Osteoporosis is the most prominent disorder of the skeleton. It is defined by the World 
Health Organization (WHO) as bone mineral density 2.5 standard deviations below 
average peak bone mass of a young sex matched healthy person, as measured by Dual 
X-ray Absorptiometry (DXA). Osteoporosis is most common in women after 
menopause where it is termed postmenopausal osteoporosis, but may develop in men 
and premenopausal women in the presence of particular hormonal disorders or other 
chronic diseases (rheumatoid arthritis, Paget’s disease of bone), or as a result of some 
medication, specifically glucocorticoids. Risks factors for osteoporosis include gender 
(female), advanced age, small skeletal frame, family history, low diet calcium and 
vitamin D, medication (glucocorticoids, anti-convulsants), low sex steroids (estrogen, 
testosterone), excessive alcohol, smoking and inactive lifestyle. Other bone disorders 
include osteogenesis imperfecta (or brittle bone disease which is a genetic disorder in 
people born with defective connective tissue or without the ability to make it, usually 
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because of a deficiency of type-I collagen), osteosarcoma (primary malignancy of bone) 
and bone metastases. 
Glucocorticoids, a key component in the management of many inflammatory disorders, 
present adverse effects particularly on bone. They increase bone resorption, inhibit bone 
formation and have indirect action on bone by decreasing intestinal calcium absorption, 
modifying vitamin D metabolism, sustaining a marked hypercalciuria with variable 
changes in plasma PTH levels (Manelli and Giustina, 2000; Tamura, et al., 2004). 
Rheumatoid arthritis is a chronic, systemic autoimmune inflammatory disorder that 
principally affects the synovial lining of joints. This inflammatory process 
(characterized by pain, swelling and stiffness) targets the articular cartilage, the bone at 
the joint margins, as well as periarticular cartilage and subchondral bone (Goldring, 
2003). Pro-inflammatory cytokines, particularly TNFα, IL-1 and IL-6, play critical roles 
in the pathogenesis of rheumatoid arthritis and are usually raised in the joint and blood 
of patients with rheumatoid arthritis (Brennan and McInnes, 2008; Christodoulou and 
Choy, 2006; Goldring, 2003). Consistent with this is the successful targeting of these 
cytokines as therapeutic intervention in the management of rheumatoid arthritis. These 
cytokines are produced by activated T cells, macrophages and fibroblasts present in the 
joint. IL-1 and TNFα, both upregulate RANKL expression in bone lining and stromal 
cells. Moreover, RANKL is expressed on T cells and fibroblasts within the synovial 
inflammatory tissue of patients with rheumatoid arthritis and its expression is 
upregulated by proinflammatory cytokines (Schett, et al., 2005). TNFα and RANKL act 
synergistically to enhance osteoclast differentiation and regulate osteoclast-induced 
focal bone loss (Goldring, 2003). Moreover, TNFα and IL-1 induce cartilage 
remodeling by stimulating the production of matrix metaloproteinases (MMPs) by 
chondrocytes. 
Paget’s disease of bone, also called osteitis deformans is a chronic disorder, 
characterized by focal areas of increased bone turnover resulting in enlarged and 
deformed bones. The disease is named after the British surgeon James Paget who first 
described it in 1877. The origin of the disease is unknown although viral 
(paramyxoviruses), genetic (mutations in Sequestosome 1 gene) and environmental 
causes have been implicated, as well as the deficiency of dietary calcium and repetitive 
mechanical loading of the skeleton (Ralston, et al., 2008). The pathogenesis of Paget’s 
disease involves 3 stages (Ralston, et al., 2008): The first step (lytic phase) is 
characterized by marked osteolysis at localized areas with abnormally increased 
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osteoclast number and nuclei (up to 100 as compared to 5-10 nuclei in normal 
osteoclasts), resulting in a bone turnover rate up to 20 times more rapid than normal. 
This significant increase in bone resorption leads to a rapid compensatory increase in 
bone formation (mixed phase) by osteoblasts, which are increased in number, but 
morphologically normal. The new bone deposition is accelerated and disorganized in a 
haphazard pattern rather than the normal linear pattern, making it mechanically weaker, 
more bulky, less compact, more vascular and liable to pathological fracture and 
deformity. In the final phase (sclerotic phase), bone formation exceeds bone resorption 
resulting in a disorganized woven bone allowing bone marrow space to be infiltrated by 
excessive fibrous connective tissue and blood vessels, leading to a hypervascular bone 
state. Eventually the hypercellularity may diminish leaving a dense “pagetic bone” 
known as the burnt-out Paget disease. 
 
1.1.3.2.2 Osteopetroses 
 
Osteopetrosis also known as marble bone disease or Albers-Schonberg disease is an 
inherited disorder, characterized by increased bone density due to poor bone removal. 
Despite the high bone mass phenotype observed, bones are generally brittle, fragile and 
therefore susceptible to fracture. The damage can be severe enough to disturb tooth 
eruption, cause marrow cavity obliteration, nerve entrapment, growth retardation, 
blindness and deafness (Zaidi, 2007). Osteopetrosis can be due to absence (impaired 
osteoclastogenesis) or dysfunctional osteoclasts. The latter case is more common with 
osteoclasts usually in normal if not elevated number, but showing defects in resorption 
components like deficiency in vacuolar H+-ATPase, chloride channel CIC-7 or 
cathepsin K genes. In humans, the most severe form is the infantile malignant 
autosomal recessive osteopetrosis arising from mutations in genes encoding 
components of the acidification machinery, namely the α3-subunit of the vacuolar 
proton pump, the chloride channel CIC-7 or carbonic anhydrase II (Frattini, et al., 2000; 
Kornak, et al., 2000; Kornak, et al., 2001; Sly, et al., 1983). A less severe form is 
observed in pycnodysostosis, a disease of dwarfism and fragile bones that results from 
cathepsin K mutation (Gelb, et al., 1996). There is no cure for most types of 
osteopetroses; but the malignant form in which carbonic anhydrase II is missing can be 
treated by bone marrow transplant. Other alternatives are the use of 1,25-dihydroxy 
vitamin D and recombinant human interferon gamma to induce osteoclast bone 
resorption. 
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1.1.3.3 Treatment of bone loss disorders 
 
Antiresorptive agents for osteoporosis are the state-of-the-art therapy, aiming to restore 
bone density by decreasing bone remodeling. Their mechanism of action is to inhibit 
bone resorption by inhibiting osteoclast generation and/or activity and by inducing 
osteoclast apoptosis. Bisphosphonates (including alendronate, ibandronate, risodronate 
and etidronate) are by far the most widely used treatment for osteoporosis, tumor 
osteolysis, humoral hypercalcemia, multiple myeloma and Paget’s disease of bone 
(Zaidi, 2007). They competitively bind to the geranyl pyrophosphate pocket of farnesyl 
pyrophosphate synthase to inhibit the mevalonate pathway of cholesterol biosynthesis in 
osteoclasts, which in turn lead to impaired prenylation of important small GTP-binding 
proteins such as Rho, and to subsequent changes in the cytoskeletal function that 
promotes osteoclast apoptosis (Mundy, 2002). Calcitonin transiently inhibits osteoclast 
activity without decreasing osteoblast collagen synthesis (Stepan, et al., 2003). Other 
antiresorptive therapies include calcium plus vitamin D and selective estrogen receptor 
modulators (raloxifene) (Vestergaard, 2005). 
Anabolic drugs are being increasingly used nowadays. They directly stimulate bone 
formation and improve bone quality and bone mass. Teriparide, the recombinant human 
parathyroid hormone (1-34), administered intermittently improves bone density, 
features of bone turnover and reduces fracture incidence, but also significantly improves 
bone microarchitectural and geometric properties (Girotra, et al., 2006). Strontium 
ranelate, another anabolic agent also inhibits bone resorption (Girotra, et al., 2006; 
Zaidi, 2007). Growth hormone (GH) and insuline-like growth factor (IGF-1) are being 
investigated as potential anabolic agents given their critical role for acquisition and 
maintenance of bone mass, although their ubiquitous effect on many organ systems 
constitute a serious drawback (Girotra, et al., 2006). 
 
1.2 Bone metastases 
 
Metastasis occurs when cancer cells break away from their primary tumour, invade the 
blood stream or lymph vessels and travel to distant organs and tissues where they settle 
in and start growing. Even after metastasis, the cancer is still named after the part of the 
body (tissue) it has started. In order to explain the bias observation that some organs 
have larger number of secondary tumours while others have relatively few, three major 
theories have been put forward (Liotta, 2001): 
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- The “Growth factor theory” holds that tumour cells leave the blood and lymphatic 
vessels to the same extent at all organs, but multiply only in those organs that have the 
appropriate growth factors. 
- The “Adhesion molecule theory” proposes that the endothelial cells that line blood 
vessels in target organs express adhesion molecules that cause circulating tumour cells 
to stop and invade those organs. 
- The “Chemokine theory” implies that organ-specific attractant molecules enter the 
circulation, stimulating tumour cells to invade the walls of blood vessels and enter the 
organs. 
Although there is evidence to support all three theories, the mediator molecules 
(whether they be growth factors, adhesion molecules or chemoattractants) have 
remained unknown until Müller et al. (Muller, et al., 2001) identified chemokines 
(CXCL12 and CCL21) in first destination target organs (lymph nodes, bone marrow 
and lungs) and chemokine receptors (respectively CXCR4 and CCR7) on human breast 
cancer cells, providing molecular support for the chemoattraction theory. 
Metastasis is a highly organized, non-random, organ-selective and numerous sequential 
step process. Different cancers tend to spread to different sites; however, bone is the 
third most common site of metastasis after the lungs and liver (Bagi, 2005). Bone 
metastasis is different, much prevalent and morbid than primary bone cancer, a cancer 
that starts in the bone. Carcinomas of the breast, lung and prostate commonly 
metastasize to the bone (Mundy, 2002), with the axial skeleton seeded more than the 
appendicular skeleton partly due to the persistence of red bone marrow in the former 
(Tofe, et al., 1975). The appearance of skeletal metastases indicates a negative 
prognostic sign that marks the stage when the disease is rarely curable and the treatment 
mainly palliative (Bagi, 2005). Manifestations of metastatic bone disease include 
pathological fractures, pain, cranial nerve palsies, spinal cord compression, bone 
marrow suppression and hypercalcemia of malignancy. 
 
1.2.1 Rules that direct cancer spread to the skeleton 
 
The skeleton is one of the most preferred sites of metastasis of malignant tumours. Over 
60 % of patients with nonosseous primary malignant neoplasms present abnormal bone 
scans (Tofe, et al., 1975) and particularly, breast, lung and prostate cancer constitute the 
major source of all metastases to bone (Tofe, et al., 1975; Tomita, et al., 2008). Indeed, 
up to 70 % of patients with advanced breast or prostate cancer, and approximately 15 to 
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30 % of patients with carcinoma of the lung, colon, stomach, bladder, uterus, rectum, 
thyroid or kidney develop bone metastases (Roodman, 2004). Moreover, the thorax (54 
%), vertebra (52 %) and pelvis (38 %) are mostly involved when compared to the skull 
(22 %) (Tofe, et al., 1975). 
Primary tumour cells invade their surrounding normal tissue by producing proteolytic 
enzymes, which degrade the walls of small blood vessels in the normal tissue or of 
those induced by the tumour, allowing the cancer cell to enter the circulation and travel 
to distant organ sites (Liotta and Kohn, 2001). (1) One of the critical determinants of the 
site of metastasis is blood flow from the primary site (breast or prostate) to the skeleton 
(Bagi, 2005). Blood flow is high in areas of red marrow, accounting for the predilection 
of metastases for those sites (Roodman, 2004). This is consistent with the “mechanical” 
hypothesis proposed by James Ewing in 1929 stipulating that patterns of blood flow 
carrying cells from the primary tumour entirely account for the unequal dissemination 
of metastases, and the first organ encountered in the circulation (lung) would harbor the 
greatest number (Fidler and Poste, 2008). However, there are other highly vascularized 
organs (kidneys, spleen) to which tumour cells rarely metastasize, implying that other 
factors are involved (Mundy, 2002). (2) More to the point, the Batson's vertebral venous 
plexus of high-volume and low-pressure vertebral veins plays a pivotal role in the 
dissemination of breast and prostate cancer to the axial skeleton (Bagi, 2005). The 
Batson’s venous system; a thin walled, valveless network of veins within and 
surrounding the vertebral column and extending from cranium to pelvis; directly 
connects primary tumour sites (breast or prostate) with the skeleton, bypassing the liver 
and lungs. The sluggish blood flow in this plexus is more conducive to tumour survival 
and facilitates extravasation of tumour cells from the circulation. (3) Last but not the 
least, aggregates of tumour cells and other blood cells (lymphocytes, platelets) 
eventually form emboli (Figure 4) that can be easily trapped in capillary beds within the 
bone (Bagi, 2005). Once the tumour cell embolus reaches the skeleton, they have a high 
probability of survival in the highly favorable bone microenvironment. This is 
supported by the “seed and soil” hypothesis proposed by Stephen Paget in 1889 stating: 
“when a plant goes to seed, its seeds are carried out in all directions; but they can only 
live and grow if they fall in congenial soil” (Fidler and Poste, 2008). This highlights the 
tightly intimate relationship (crosstalk) that the cancer cell (seed) must entertain with its 
environment (soil) in order for a metastasis to be established. 
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Figure 4. Steps involved in tumour cell metastasis from the primary site to the 
skeleton (Mundy, 2002) 
 
The tumour cells must possess the capacity to migrate across the sinusoid wall of the 
blood vessel, invade the marrow stroma, build their own blood supply and travel to the 
endosteal bone surface to stimulate the activity of osteoclasts or osteoblasts, thereby 
determining whether the following bone metastasis is osteolytic or osteoblastic (Mundy, 
2002). 
 
1.2.2 Bone microenvironment, interaction between cancer and bone cells: the 
vicious cycle 
 
Bone is the first site of androgen-independent prostate, and second site (after lungs) of 
estrogen-independent breast cancer progression (Bagi, 2005). As a matter of fact, the 
bone microenvironment, as well as the interaction between bone and cancer cells plays 
a crucial role in the development and progression of skeletal metastases. In normal 
physiological conditions, bone remodeling is tightly regulated; with bone resorption 
coupled to bone formation to ensure that the amount of old bone resorbed equals the 
amount of new bone deposited. However, colonization of the skeleton by tumour cells 
(mainly from breast and prostate) disturbs this equilibrium, leading to dramatic changes 
in bone resorption (lytic tumours), bone formation (blastic tumours) or both (mixed 
tumours). 
The bone matrix harbors many growth factors that are released in the bone marrow 
cavity following osteoclastic activity. These growth factors include IGF-1, TGFß, FGFs 
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and PDGFs. IGF-1, the most abundant growth factor stored in bone promotes tumour 
cell proliferation, chemotaxis and survival whereas TGFß and Ca2+, also stored in large 
amount in bone, stimulate cancer cell production of PTHrP (Mundy, 2002; Yoneda and 
Hiraga, 2005). PTHrP then signals in osteoblasts/stromal cells through binding on PTH 
receptors to increase production of RANKL, a cytokine that plays a central role in 
osteoclast differentiation and activation (Yoneda and Hiraga, 2005). This consequently 
leads to increased osteoclastic bone resorption, with released of growth factors that feed 
back to tumour cells to further stimulate growth and metastasis, creating a “vicious 
cycle” (Bagi, 2005; Mundy, 2002; Yoneda and Hiraga, 2005): resorbed bone releases 
TGFß and IGF-1, thereby stimulating cancer cell growth and further production of 
PTHrP, which in turn causes more bone resorption, release of growth factors and 
subsequent stimulation of tumour cell proliferation. Therefore, osteoclastic activity 
transforms the bone milieu into a “fertile soil” by triggering release of bone stored 
growth factors and mineral components that support cancer cell growth, establishment 
and progression of metastases (Figure 5). 
 
Figure 5. Communication between bone cells and cancer cells in bone metastasis 
(Yoneda and Hiraga, 2005) 
 
Although being a fertile milieu confers the bone a very attractable target for metastasis, 
this feature in itself is not sufficient, and in order for metastasis to occur, tumour cells 
must possess unique biological properties or molecular signatures. In this regard, they 
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should be able to overproduce PTHrP, activate matrix metalloproteinases (MMP-2, 
MMP-9), downregulate E-cadherin, express elevated levels of integrins, osteopontin, 
bone sialoprotein and chemokine receptors (CXCR4, CCR7) (Yoneda and Hiraga, 
2005). 
 
1.2.3 Pathophysiology of bone metastases 
 
Once in the local bone microenvironment, tumour cells closely interact with bone cells 
(osteoblasts and osteoclasts), as well as hematopoeitic and stromal cells to deregulate 
the normal bone remodeling mechanisms. Depending on the effect of tumour-secreted 
factors on bone resorption or bone formation, two major metastatic phenotypes have 
been described (Bagi, 2005; Mundy, 2002). The osteolytic phenotype is caused by 
osteoclast-activating factors that boost out bone resorption while the osteoblastic 
phenotype results from osteoblast-activating factors that stimulate osteoblast 
proliferation, differentiation and bone formation. Breast cancer metastasizing to bone 
usually causes osteolytic metastases whereas prostate cancer results in osteoblastic 
metastases. However, the concept of bone metastases as being either osteolytic or 
osteoblastic is somewhat overrated, as up to 25 % of patients with bone metastases from 
breast cancer also show blastic lesions that are similar to those with metastatic prostate 
cancer, and some patients with prostate cancer have lytic lesions that are comparable to 
those seen in metastatic breast cancer patients (Mundy, 2002). This has given rise to an 
additional phenotype, the so-called mixed tumours. Interestingly, lytic and destructive 
lesions are predominant with reduced osteoblast activity in the case of metastatic breast 
tumour, as opposed to predominant blastic lesions associated with resorptive 
components in metastatic prostate tumour. Yet, some types of metastases, particularly 
from myeloma, cause solely osteolytic bone lesions (Bagi, 2005; Mundy, 2002). 
Osteolytic lesions are associated with massive bone destruction leading to pain, 
pathological fractures and disability, seriously affecting cancer patient quality of live 
and worsening the prognosis. Although osteoblastic metastasis is less harmful to bone 
morphology and has lesser impact on bone health as compared to lytic tumours, it is 
very unlikely that the newly randomly deposited bone with woven internal structure 
(rather than linear) fulfills any mechanical function in the skeleton (Bagi, 2005). 
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1.2.3.1 Mechanism of osteolytic metastases 
 
Bone resorption through the action of osteoclasts is likely to be the main mechanism in 
the early stages of bone metastasis, and is probably the main mechanism by which 
osteolysis (particularly in breast and prostate cancer) progresses (Bagi, 2005). The 
peptide PTHrP released by breast tumour cells is the main mediator of osteoclast 
activation (Bagi, 2005; Mundy, 2002). This is in line with the findings that breast 
cancer cells that have metastasized to the bone produce elevated levels of PTHrP than 
do those remained in the primary site or those who have metastasized to soft tissues 
(Mundy, 2002). More to the point, the resulting osteolysis was shown to be blocked by 
neutralizing antibodies against PTHrP. PTHrP stimulates production of RANKL by 
Osteoblasts/stromal cells, which in turn binds to its receptor RANK on osteoclasts and 
osteoclasts precursors to enhance osteoclast differentiation and bone resorption. If it is 
now widely accepted that cancer cells by themselves do not have the ability to resorb 
the bone, they do however produce the osteoclastogenic cytokine RANKL, and whether 
or not this particular RANKL produced by tumour cells is sufficient to activate 
osteolysis is still a matter of debate (Mundy, 2002). Other osteoclastogenic factors 
produced by cancer cells include TNFα and ß, IL-1, 6, 8 and 11, estrogen receptors, 
PTH receptors, as well as TGFα and ß (Bagi, 2005; Mundy, 2002). Osteoclasts are 
pivotal in the pathogenesis of tumour-associated osteolysis, as they are directly 
responsible for focal bone loss at metastatic sites, as well as the release of bone stored 
growth factors (IGF-1, TGFß, FGFs, PDGF, BMPs) into the local environment that feed 
back to stimulate tumour cell growth. Other causes of cancer-associated bone loss may 
be deprivation of sex steroids, disuse or immobilization, use of cytotoxic cancer 
therapies, radiation therapy and use of palliative therapies such as glucocorticoids. 
 
1.2.3.2 Mechanism of osteoblastic metastases 
 
Osteoblastic lesions occur most commonly in prostate cancer and result from a direct 
stimulation of osteblast proliferation and bone formation by tumour-secreted factors. 
One of the best well-characterized mediators is the growth factor endothelin-1 (Bagi, 
2005; Mundy, 2002). Other factors include IGFs, TGFß, FGFs, BMPs, uPA, PSA and 
the B isoform of PDGF. 
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1.3 Cyclodepsipeptides 
 
Depsipeptides are a group of natural or synthetic compounds having sequences of 
amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha hydroxy 
acids), commonly but not necessarily regularly alternating and joined by amide and 
ester bonds. In cyclodepsipeptides, the residues are connected in a ring. 
Cyclodepsipeptides have been isolated from bacteria, actinomycetes and fungi. The 
recent years have witnessed a tremendous effort in the identification of these 
compounds, mostly motivated by the large scope of their biological activities and 
therapeutic opportunities. They are lipophilic ionophores, which are readily 
incorporated into cell membranes, forming cation selective pores that allow ions to pass 
through (Firakova, et al., 2007; Lemmens-Gruber, et al., 2009). In this regard, they 
greatly influence cell membrane permeability and action potential. Additionally, their 
antibiotic, insecticidal, anthelmintic, antimicrobial, phytotoxic, antimalarial and 
cytotoxic properties are established (Firakova, et al., 2007; Lemmens-Gruber, et al., 
2009). It is believed that the cyclic structure of the depsipeptide is essential for the 
biological activity, as their linear homologues are inactive (Lemmens-Gruber, et al., 
2009). 
Beauvericin and enniatins are well-described, structurally related 
cyclohexadepsipeptides (six residues connected in a ring) mycotoxins produced by 
Fusarium (Audhya and Russell, 1974; Doel, et al., 1978; Gupta, et al., 1991; Logrieco, 
et al., 1998; Logrieco, et al., 2002), Beauveria (Hamill, et al., 1969; Suzuki, et al., 
1977), Paecylomyces (Bernardini, et al., 1975) and Polypovirus (Doel, et al., 1978). 
They occur in food contaminated grain samples (corn, wheat, barley, feed) (Logrieco, et 
al., 2002; Jestoi, et al., 2004; Uhlig, et al., 2004). However, the health risk for the 
population following exposure to these toxins is still unclear and may be underestimated 
as to date, there have been no convincing data to shed light on the topic. They have been 
proven to be phytopathogenic, endowed with antibiotic, insecticidal (Grove and Pople, 
1980; Guadet, et al., 1989; Gupta, et al., 1991), hydrophobic (Tomoda, et al., 1992), and 
ionophoric properties (Kamyar, et al., 2004; Kouri, et al., 2003; Kouri, et al., 2005), and 
have been reported to inhibit acyl-CoA: cholesterol transferase (Tomoda, et al., 1992), 
the enzyme that catalyzes the conversion of cellular cholesterol and long chain fatty 
acyl-CoA into cholesteryl ester. 
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1.3.1 Beauvericin 
 
Beauvericin was first isolated in the fungus Beauveria bassiana (Hamill, et al., 1969), 
but is also produced by several other fungi including Fusarium, and is active against 
Gram-positive bacteria and mycobacteria (Castlebury et al., 1999; Fotso and Smith, 
2003). Chemically (Figure 6), beauvericin is a cyclic hexadepsipeptide with alternating 
methyl-phenylalanyl and hydroxyl-iso-valeryl residues. 
 
 
Figure 6. Chemical structure of beauvericin and enniatins (Uhlig, et al., 2004) 
 
Beauvericin is not mutagenic (Fotso and Smith, 2003), but rather cytotoxic to several 
mammalian cell line models, including the murine P815 mastocytoma cells, Yac-1 
lymphoma cells and EL-4 thymoma cells (Ojcius, et al., 1991); the rat mast cell like 
RBL-1 cells, the simian fibroblastoid CV-1 cells and the human IARC/BL 41 cells 
(from Burkitt’s lymphoma), HeLa cells (from cervical carcinoma) and Hep G2 cells 
(from hepatoma) (Logrieco, et al., 2002; Macchia, et al., 1995); the human monocytic 
cells U-937 and promyelocytic leukemia cells HL-60 both of myeloid origin (Calo, et 
al., 2004); the human lymphoblastic leukemia cells (CCRF-CEM) (Jow, et al., 2004) 
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and the porcine kidney PK15 cells (Klaric, et al., 2008). In particular, beauvericin 
induces programmed cell death similar to apoptosis, and causes cytolysis accompanied 
by internucleosomal DNA fragmentation into 200 bp (Macchia, et al., 1995; Ojcius, et 
al., 1991). Beauvericin induced cytotoxicity has been shown to be mediated by 
increased intracellular Ca2+ calcium influx, either from internal stores (Jow, et al., 2004; 
Ojcius, et al., 1991), or by extracellular Ca2+ influx via the plasma membrane prior to 
the increased intracellular Ca2+ apoptotic effect (Tang, et al., 2005). 
 
1.3.2 Enniatins 
 
Enniatins are secondary metabolites produced predominantly by the fungi Fusarium 
during an enzymatic reaction catalyzed by enniatin Synthetase. Their anthelminthic, 
anti-HIV-1 and antimalarial activities have been reported (Firakova, et al., 2007; 
Lemmens-Gruber, et al., 2009). Likewise beauvericin, enniatin was found not to be 
mutagenic at toxic concentrations (Behm et al., 2009). Interestingly, enniatins have been 
shown to act as potent inhibitors of drug efflux pumps (ATP-binding cassette 
transporters), thereby holding promise for the management of multidrug resistance that 
usually occurs in bacterial resistance or cancer therapy due to pumping of 
chemotherapeutics out of the cells (Firakova, et al., 2007). Dornetshuber et al. 
(Dornetshuber, et al., 2007) have reported slight, but significant tumor-promoting effect 
after short term exposure (up to 8 hours) of human mammalian cells to nanomolar 
concentrations of enniatin, as compared to its apoptotic-inducing effect at low 
micromolar concentrations already after 24 hours treatment. 
 
1.4 Scope of the study 
 
Bone loss occurs when bone resorption by osteoclasts uncouples from bone deposition 
by osteoblasts, either temporally or spatially. In low turnover bone loss, bone formation 
slows down and lags behind bone resorption, condition that prevails in aging, disuse 
and glucocorticoids medication. However, in high turnover bone loss, bone resorption 
dominates and can be generalized as observed in hyperparathyroidism, sex steroids 
deprivation (estrogens and androgens) and thyrotoxicosis; or localized in focal 
osteolysis observed in rheumatoid arthritis, Paget disease of bone, periodontitis and 
skeletal metastases. These disorders are associated with bone pain, pathological 
fractures, hypercalcemia and disability; seriously compromising bone health and 
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severely affecting a patient’s quality of life. The past decade has witnessed remarkable 
advances in our understanding of the pathogenesis of these bone disorders. It is now 
clear that the osteoclast is the principal culprit of these conditions, and therefore 
represents the first choice therapeutic target. Biphosphonates are by far the gold 
standard for the management of bone loss, as they directly inhibit osteoclast activity and 
survival. However, their therapeutic use is narrowed by frequent side effects like on the 
oesophagus and rare but serious side effects like osteonecrosis of the jaw, calling for 
new medications. 
Cyclodepsipeptides are mycotoxins with an immense spectrum of biological activities, 
ranging from ionophoric, antibiotic, insecticidal, phytotoxic, anthelminthic and 
antimalarial to cytotoxic. Recently, cyclodepsipeptides dextruxins were reported to 
inhibit bone resorption without affecting osteoclast differentiation and survival 
(Nakagawa, et al., 2003), bringing evidence for the first time that cyclodepsipeptides 
could actually affect bone resorbing cells, and consequently raising the need of 
screening other cyclodepsipeptides for their antiresorptive effects. Beauvericin and 
enniatins, their related homologues, have been proven cytotoxic to several mammalian 
cell lines models and tumour cells. However, their effect on bone cells, namely 
osteoblasts and osteoclasts, remains yet to be elucidated. Given the effect of dextruxins 
on osteoclasts, it is anticipated that beauvericin and enniatins might exhibit these 
inhibitory properties as well. 
Increased osteoclast activity is observed during osteolytic tumour metastasis. The 
crosstalk between tumour cells and bone cells (osteoblasts and osteoclasts) in the bone 
microenvironment, the so-called vicious cycle, is determinant for the establishment and 
progression of metastasis. As bone resorption is likely to be the main mechanism in the 
early stages of bone metastasis, and probably the main mechanism by which osteolysis, 
particularly from breast and prostate cancer patient progresses (Bagi, 2005), an effect of 
beauvericin and enniatins on osteoclasts is therefore likely to impact on the tumour cell 
itself in the local bone milieu. As a consequence, it was also of interest to examine the 
direct effect of beauvericin and enniatins on tumour cells that have the ability to 
metastasize to the bone. 
The aim of this study was to characterize pharmacological and toxicological effects of 
two structurally related cyclohexadepsipeptides mycotoxins beauvericin and enniatins 
on bone cells (osteoblasts and osteoclasts), as well as on cancer cell lines (MDA-MB-
231, PC3 and U2OS). 
More specifically, this study aimed to: 
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- examine the effect of beauvericin and enniatins on osteoclast differentiation, 
cytoskeleton, activity, survival and apoptosis; 
- evaluate the effect of beauvericin and enniatins on cell viability and apoptosis of 
osteoclast precursors (osteoblasts and RAW 264.7); 
- establish the signal transduction pathways affected in RAW 264.7 and coculture-
derived osteoclasts following exposure to beauvericin and enniatins; 
- investigate the effect of beauvericin and enniatins on the proliferation, viability and 
apoptosis of metastatic breast (MDA-MB-231) and prostate (PC3) cancer cell lines, as 
well as on a primary tumour of bone cell line (U2OS); 
- elucidate the molecular signaling pathways of beauvericin and enniatins in these 
metastatic and non metastatic cell lines. 
 
1.5 Presentation of the thesis 
 
This work is subdivided in 4 main sections: an introduction with aim and objectives 
(behind) followed by a materials and methods section. The outcome of the experimental 
work is presented in 2 parts (manuscript 1 and manuscript 2). Each manuscript is a 
complete paper formated according to Biochemical Pharmacology Journal with figures 
located at the end just before the references. The last section is the summary and 
conclusion. 
The bibliography section of this thesis contains complete references of the citations in 
the introduction section. 
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2 Materials and methods 
 
2.1 Materials 
 
2.1.1 Commonly used solutions and buffers 
 
a) PBS without Ca2+/Mg2+ 10X: 2.00 g KCl, 2.00 g KH2PO4, 80.00 g NaCl, 27.07 
g Na2PO4.2H2O, 1000 ml distilled H2O. Mixed to dissolve, this solution is 
diluted 1:10 with distilled H2O, sterile filtrated before use and stored at 4 °C. 
 
b) PBS with Ca2+/Mg2+ 10X: 1.00 g CaCl2 (anhydrous), 2.00 g KCl, 2.00 g 
KH2PO4, 1.00 g MgCl2.6H2O, 14.34 g Na2HPO4.2H2O, 80.00 g NaCl, 1000 ml 
distilled H2O. Mixed to dissolve, this solution is stored at 4 °C. Dilute 1:10 with 
distilled H2O and adjust the pH to 7.2 using NaOH 5N before use. 
 
c) TBS 10X: 24.20 g Tris base, 80.00 g NaCl, 1000 ml distilled H2O. Mixed to 
dissolve, this solution is immediately diluted 1:10 with distilled H2O for the 
preparation of TBS 1X and the pH adjusted to 7.6 using 37 % HCl. To prepare 
TBST 0.1 % and 0.3 %, 1 liter of TBS 1X is diluted with 1 ml and 3 ml of 
Tween 20 respectively. 
 
d) Running buffer 10X: 286.50 g glycerin, 60.50 g Tris base, 40.00 g SDS, 2000 
ml distilled H2O. Mixed to dissolve, this solution is stored at room temperature. 
Dilute 1:10 with distilled H2O and adjust the pH to 8.9 before use. 
 
e) Transfer buffer: 36.00 g glycerin, 7.53 g Tris base, 4000 ml distilled H2O. Mix 
to dissolve and adjust the pH to 8.3. This solution is stored overnight at 4 °C, 
then completed with 1000 ml methanol and stored at 4 °C. 
 
f) Sample buffer 4X: 6.06 g Tris base, 9.45 g glycerin, 6.00 g SDS, 0.20 g 
bromophenol blue, 0.11 g EDTA, 50 ml distilled H2O. Mixed to dissolve, this 
solution is stored at –20 °C. 
g) Stripping buffer 1X: 9.31 g Tris HCl, mix to dissolve with 800 ml distilled H2O, 
adjust the pH to 6.8 using NaOH 5N, add 20.00 g SDS, mix and adjust the 
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volume to 1000 ml with distilled H2O. This solution is stored at 4 °C and always 
supplemented with ß-mercaptoethanol (700.00 µl ß-mercaptoethanol in 100 ml 
stripping buffer) before use. 
 
h) Lower Tris buffer: 18.17 g Tris base, mix to dissolve with 800 ml distilled H2O, 
adjust the pH to 8.8 using 37 % HCl, add 4.00 g SDS and complete the volume 
to 100 ml with distilled H2O. This solution is sterile filtrated using a folded filter 
paper and stored at 4 °C. 
 
i) Upper Tris buffer: 6.06 g Tris base, mix to dissolve with 800 ml distilled H2O, 
adjust the pH to 6.8 using 37 % HCl, add 4.00 g SDS and complete the volume 
to 100 ml with distilled H2O. This solution is sterile filtrated using a folded filter 
paper and stored at 4 °C. 
 
j) Ponceau red solution 0.2 %: 0.20 g ponceau S, 3.00 g Trichloro acetic acid, 100 
ml distilled H2O. Mixed to dissolve, this solution is stored at room temperature. 
 
k) NaN3 solution 500X: 0.10 g NaN3, 1 ml distilled H2O. Mixed to dissolve, this 
solution is stored at 4 °C. 
 
l) Lysis buffer 1.50 ml: 1.50 ml Frackelton lysis buffer, 75.00 µl NaF (1 M), 7.50 
µl Aprotinin (2 mg/ml), 15.00 µl Leupeptin (1 mg/ml), 1.50 µl Pepstatin (1 
mg/ml), 15.00 µl Orthovanadate (200 mM), 15.00 µl PMSF (100 mM). Mix to 
dissolve. This solution is prepared immediately before use. 
 
m) Blocking solution 5 % non fat dry milk: 1.25 g dry milk (fix milk), 25 ml TBST 
0.1 %. Mix to dissolve at +80 °C. This solution is prepared immediately before 
use. 
 
n) Trypsin/EDTA 10X: 0.25 g trypsin (1:250), 0.20 g EDTA, 10 ml PBS without 
Ca2+/Mg2+ 1X. Mix to dissolve. This solution is sterile filtrated and stored at – 
20 °C. Dilute 1:10 with sterile PBS without Ca2+/Mg2+ 1X before use. 
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o) Toluidine blue staining solution 1 %: 1.00 g sodium borate, 1.00 g toluidine blue 
O, 100 ml distilled H2O. Mix to dissolve and store at room temperature. 
 
2.1.2 Gel for electrophoresis 
 
a) Running gel 10 %: 1430 µl H2O, 880 µl Lower Tris buffer, 1170 µl acrylamide, 
1.05 µl TEMED, 17.50 µl APS. Mixed to dissolve, this solution is used 
immediately for one gel of a Bio-Rad Minigel system (Mini-Protean II). 
 
b) Stacking gel 10 %: 945 µl H2O, 375 µl Upper Tris buffer, 195 µl acrylamide, 
2.04 µl TEMED, 15 µl APS. Mixed to dissolve, this solution is used 
immediately for one gel of a Bio-Rad Minigel system (Mini-Protean II). 
 
2.1.3 Tartrate resistant acid phosphatase (TRAP) staining solution 
 
a) TRAP buffer: 0.11 g Na-acetate, add 20 ml of distilled H20, adjust the pH to 5 
using HCl 1M, add 0.046 g Na-tartrate. Mix to dissolve. 
 
b) Naphtol solution: 0.005 g naphtol AS-MX phosphate, 500 µl N,N-dimethyl 
formamide. Mix to dissolve. 
 
c) Staining solution: 9 ml TRAP buffer, 90 µl naphtol solution, 5.40 mg fast red 
violet salt. Mix to dissolve by sonicating 5 minutes in ultrasound bath. 
 
2.1.4 Equipments and supply 
 
2.1.4.1 Equipments 
 
Equipments     Company name 
Autoclave Tomy SX–300E, Tomy Kogyo Co..LTD, 
Japan 
Bone saw Isomet Low Speed Saw, Buehler, USA 
Centrifuges Hermle Z323K, Hermle, Germany 
SORVALL® RT7, Minnesota, USA 
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Cell counter + analyzer Casy1 Model DT Schärfe system, 
Germany 
Computers Power Macintosh, Windows 2000 or XP 
Digital camera Coolpix 995, Nikon, Japan 
Digitalization table KT-0405-A, Wacom, Japan 
Electrophoresis mould Protean II xi Slab Cell, Bio-Rad, USA 
ELISA-reader Labsystems Multiskan MS, Labsystems, 
Finland 
Eppendorf centrifuge Eppendorf centrifuge 5415 C, Eppendorf, 
Germany 
Eppendorf thermomixer Eppendorf Thermomixer 5436, Eppendorf, 
Germany 
Fluorescence microscope Optiphot2-UD, Nikon, Japan 
Hemocytometer IVO, Germany 
Ice machine Scotsman AF–10, Germany 
Incubators Hera Cell 240, Kendro®, Germany 
Modell 500, Memmert, Germany 
Inverted microscopes Diaphot 300, Nikon, Japan 
TMS, Nikon, Japan 
Laminar air flow Ehret Reinraum Technic, Germany 
Light source for microscope KL 1500 Electronic, Schott, North 
America 
Magnetic stirer Ikamag RCT, Germany 
Microscope Olympus BX51, Japan 
pH-Meter 713 pH Meter, Metrohm, Switzerland 
Saw blades Diamond wafering blades/series 15 HC 
Diamond, Buehler, USA 
Scales LC 621 P, Sartorius, Austria 
MC 210 P, Sartorius, Austria 
Shaker Swip, Edmund Bühler, Germany 
Shaking incubator GFL® 3032, Burgwedel, Germany 
Sterilizer WTC Binder, Germany 
Ultrasound bath Transsonic T 570, Elma, Germany 
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Ultra pure water system Milli-QUF PLUS, Millipore 
Video camera DXC-ISIAP, Sony, Japan 
Vortex Vortex Genie 2TM, Bender & Hobein AG, 
Zurich, Switzerland 
Water baths GFL® 1086/1092, Burgwedel, Germany 
Water purification system Milli-RO 5 PLUS, Millipore 
 
2.1.4.2 Supply 
 
Supply     Company name  
Centrifuge tubes 15 and 50 ml, cell 
scrapers 
Sterilin, Bibby Sterilin Ltd., UK; 3010 
Costar, Cambridge, USA 
Coverslips (22 x 22 mm) and microscope 
slides (76 x 26 mm) 
Menzel-Glaser, Germany 
Cryogenic vials Falcon, Becton Dickinson, USA 
Eppendorf tubes Eppendorf, Germany 
Glass pipettes 5, 10, 20 and 25 ml Silber Brand, Germany 
Injection needles 27G3/4 0.4x19 Nr20 Becton Dickinson, Ireland 
Nitrocellulose membrane 0.45 µm and gel 
blotting filter paper 
Whatman Schleicher & Schull, Dassel, 
Germany 
Plastic pipettes 1, 5, 10 and 25 ml Costar, Corning Incorporated, USA 
Polystyrene round-bottom tubes 5 ml BD FalcconTM, USA 
Silicon GE Bayer Silicones, USA 
Syringes 1, 5 and 10 ml Terumo Europe, Belgium 
Tissue culture plates-6, 12, 24, 48, 96-well 
plates 
Costar, USA; Falcon, USA; Greiner Bio-
one, Germany; Iwaki, Japan; Nunc, 
Denmark 
Tissue culture dishes-2, 5 and 10 cm Iwaki, Japan; Sterilin, UK 
Amersham HyperfilmTM ECL GE Healthcare, Japan 
 
2.1.5 Cells, culture media, sera 
 
- Osteoblasts were isolated from the calvariae of new-born mice (1 to 2 days old); 
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- Bone marrow cells were extracted from the femora and tibiae of 6 to 8 weeks 
old mice; 
- The monocyte-macrophage cell line RAW 264.7 was obtained from American 
Type Culture Collection (ATCC) (Manassas, VA, USA); 
- The metastatic breast cancer MDA-MB-231, the metastatic prostate cancer PC3 
and the osteosarcoma cell line U2OS were also obtained from the ATCC; 
- α-MEM (Alpha modification of the minimum essential medium) was purchased 
from Gibco, Invitrogen, UK; 
- α-MEM containing 2 mmol/l glutamax was from Gibco, Invitrogen, UK; 
- Fetal calf serum (FCS) was from Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany. 
 
2.1.6 Test substances 
 
The substances used were 2 cyclohexadepsipeptides, beauvericin (#B-7510) and 
enniatins (#E-3643), both produced as a desiccate by Sigma Aldrich Chemie, 
Taufkirchen, Germany. 
Enniatins (ENN) had a purity of approximately 96 %, a molecular weight of 681.5 
g/mol and was composed of 3 % enniatin A, 20 % enniatin A1, 19 % enniatin B and 54 
% enniatin B1. Beauvericin (BEA) was of 99 % purity with a molecular weight of 784 
g/mol. The concentrations used ranged from 0.01 µM to 10 µM. The substances were 
dissolved in absolute ethanol to make stock solutions at 0.1 mM, 1 mM and 10 mM. 
The substances are light sensitive; therefore, the desiccates were stored dark at 4 °C and 
the stock solutions at – 80 °C. 
 
2.2 Methods 
 
2.2.1 Cell culture and maintenance 
 
- Primary osteoblasts (OB) were maintained in α-MEM supplemented with 10 % 
heat inactivated FCS (Sigma, lot 114k3395), 100 U/ml penicillin (Life 
Technologies Inc. Grand Island, USA) and 100 µg/ml streptomycin (Life 
Technologies Inc. Grand Island, USA); 
Materials and methods 
 
35 
- RAW 264.7 cells were cultured in α-MEM containing glutamax (2 mmol/l) 
enriched with 10 % heat inactivated FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, in the presence or absence of 50 ng/ml rm RANKL (R&D 
systems, Minneapolis, MN, USA); 
- Bone marrow cells were isolated from femora and tibiae, and cocultured with 
osteoblasts in α-MEM enriched with 10 % FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 1 µM PGE2 (#14010, Cayman Chemical, USA) and 1 nM 1,25 
(OH)2 vitamin D3 (#R0 21-5535, Hoffmann-La Roche AG, Basel, Switzerland); 
- Cancer cells (MDA-MB-231, PC3 and U2OS) were grown in α-MEM 
supplemented with 10 % heat inactivated FCS, 100 U/ml penicillin and 100 
µg/ml streptomycin. 
All cells were maintained at 37 °C in a humidified atmosphere of 5 % CO2 in air. The 
cells were refreshed every 2 or 3 days with new medium according to the specific 
requirements of each cell line. 
 
2.2.2 Splitting 
 
Cells were grown on tissue culture dishes until confluency. Confluent cells were 
washed (with 37 °C warm PBS without ca2+/Mg2+) and detached from the culture dishes 
by enzymatic digestion using 37 °C warm 1X trypsin/EDTA or otherwise mentioned. 
Following enzymatic digestion, cells were collected in centrifuge tubes and spun down 
at 1500 rpm for 5 min at 4 °C. The pellet was resuspended in culture medium and the 
cells seeded and allowed to proliferate onto new culture dishes with splitting rates of 
1:4. 
 
2.2.3 Freezing 
 
Following enzymatic digestion, cells were pelleted, resuspended in new medium, and 
counted using the Casy cell counter + analyzer system. The counted cells were pelleted 
again and resuspended in a defined volume of freezing medium (50 % heat inactivated 
FCS, 40 % α-MEM and 10 % DMSO). About 4 millions cells in 1.5 ml freezing 
medium were aliquoted in cryogenic vials. The latter were immediately placed in 
freezing containers (Nalgene, USA) with isopropanol and stored for overnight at –80 °C 
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to allow freezing at a constant rate of -1 °C/min. These vials were later transferred in 
liquid nitrogen tanks for long term storage. 
 
2.2.4 Primary osteoblast isolation 
 
Primary OB were isolated by sequential collagenase IV (#C9891, Sigma-Aldrich St. 
Louis, MO, USA)/dispase II (#165859, Boehringer Mannheim, IN, USA) digestion of 
calvariae from 1 to 2 days old mice. The calvariae were extracted, washed in cold PBS 
without Ca2+/Mg2+ and transferred in a 50 ml centrifuge tube with cold PBS without 
Ca2+/Mg2+. Thereafter, calvariae were digested four times for 10 min each and the last 
time for 20 min with enzyme solution (0.1 % collagenase IV, 0.2 % dispase II, α-MEM 
free of serum and antibiotics) in a shaking incubator at 37 °C, 200 rpm. The supernatant 
of the first digestion step (fraction I) was discarded, and the 4 other fractions were 
pulled together in a fresh centrifuge tube and pelleted at 1500 rpm, 4 °C for 10 min. The 
cells were resuspended in α-MEM containing 10 % heat inactivated FCS, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and seeded in 10 cm tissue culture dishes (cells 
from 10 calvariae in one dish). After 24 hours, the cells were refreshed with new 
medium and cultured until confluency (one more day). The cells were then splitted, 
cultured until confluency again (2 days) and frozen. 
 
2.2.5 Preparation of mouse osteoclasts-like cells from bone marrow 
 
6 to 8 weeks old mice were killed by cervical dislocation and their femora and tibiae 
were aseptically isolated and placed in a 10 cm dish with either sterile PBS without 
Ca2+/Mg2+ or an old culture medium. The muscles were removed under sterile 
conditions and the marrow cavity was flushed out with α-MEM containing 10 % FCS 
for bone marrow, using a G27 hypodermic needle and a 1 ml syringe. The cells were 
homogenized, transferred in a 50 ml centrifuge tube and pelleted at 1500 rpm for 5 min 
at 4 °C. The bone marrow cells were then resuspended and cocultured (cells from one 
femur bone in 12 wells of a 48-well plate) with primary osteoblasts isolated from 1 to 2 
days old mice calvariae (1 million osteoblasts in 12 wells of a 48-well plate) on either 
bone slices (for pit assays and attachment on bone surface), coverslips (for attachment 
on glass surface) and/or on culture dishes (for attachment on plastic surface). The cells 
were submitted to osteoclastogenic conditions (1 µM PGE2 and 1 nM 1,25 (OH)2 
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vitamin D3), together with the pharmacological compound (BEA or ENN) and 
maintained in culture for 5 to 6 days at 37 °C and 5 % CO2. The cells were refreshed 
every 2 days with new medium and after culture, they were submitted to TRAP staining 
for trapping of multinucleated cells with 3 or more nuclei. 
 
2.2.6 Preparation of rabbit osteoclasts 
 
Osteoclasts (OC) were isolated from long bones of 5 days-old New Zealand white 
rabbits. They were transferred onto plastics, coverslips or bone specimens and first 
incubated for 2 hours in α-MEM (with 10 % FCS heat inactivated, 100 U/ml penicillin 
and 100 µg/ml streptomycin), then rinsed to remove most of the contaminating cells and 
thereafter incubated for 24 hours in the presence or absence of different concentrations 
of the test compounds. 
 
2.2.7 Preparation of bovine bone slices 
 
Bovine bone was previously isolated from cattle, dried for 24 hours at 50 °C and stored 
in cooling conditions (4 °C). Bone was cut into slices of 300-350 µm thickness using a 
low speed Isomet saw with diamond blade. The slices were further cut into small pieces 
of equal square (4 mm x 4 mm) that could fit neatly 4 by 4 in a well of 48-well plate. 
Thereafter, the bone slices were sonicated 3 times for 5 min each in distilled water and 
one time for 5 min in 70 % ethanol. Under the laminar air flow, the bone slices were 
tagged (scratch with the pencil) on one side, and each side was UV-radiated for 15 
minutes. The bones were then glued on sterile silicone, 4 per well in a 48-well plate, the 
marked side down, and preincubated for at least 2 hours or overnight in α-MEM with 
10 % heat inactivated FCS, 100 U/ml penicillin and 100 µg/ml streptomycin (0.5 ml 
total volume per well) at 37 °C, 5 % CO2. 
 
2.2.8 Measurement of bone resorption 
 
Bone marrow cells (1 femur bone for 12 wells of a 48-well plate) were cocultured with 
OB (1 million cells for 12 wells of a 48-well plate) on bone slices (4/well) under 
osteoclastogenic conditions (1 µM PGE2 and 1 nM 1,25 (OH)2 vitamin D3) for 5 to 6 
days in the presence of the pharmacological compound (BEA or ENN). At the end of 
the culture, the bone slices were removed from the wells and given in polystyrene tubes 
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with 70 % isopropanol (not more than 8 bones slices per tube). The bones slices were 
then sonicated for 15 min to ensure complete washing of adherent cells and rests of 
silicone, then dried on a clean towel paper and incubated 1/well in a 24-well plate, with 
700 µl of 1 % toluidine blue each for 4 min on a shaker at room temperature. Staining 
with toluidine blue made it possible to see the resorption areas under the microscope. 
Afterwards, the bone slices were rinsed in 3 changes of distilled water, dried and stored 
in a 96-well plate (1/well) until pit area measurement. The areas of osteoclast resorption 
lacunae were visualized using an Olympus BX51 microscope with a 5x magnification 
under oblique light. 2 pictures per bone slice were taken with the camera (intelligent 
exposure) of the Cell * F computer program (one at the left upper corner and the other 
at the right lower corner). The 2 pictures were further combined in one picture on which 
pit areas were traced and analyzed using the digitalization table and pen of the Cell * F. 
For each bone slice, the software automatically calculated the sum of all pits areas and 
the total bone surface on which pits areas were traced. These results were then copied in 
Microsoft Excel which gave us the percentage of resorption /bone slice. 
 
! 
% resorbed area =
total area of pits
total area of bone slice
*100  
 
2.2.9 TRAP staining of osteoclasts 
 
Cells cultured on plastic surfaces or on coverslips were washed with 37 °C warm PBS 
with Ca2+/Mg2+, fixed with 3.7 % formaldehyde (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany) for 3 and 10 min, washed with PBS again and stored at 4 °C in 
PBS with Ca2+/Mg2+ containing Sodium azide to prevent infection. Thereafter, the cells 
were incubated with the TRAP buffer for 30 min at 37 °C, 5 % CO2. Following 
incubation in alcohol/acetone solution (v/v) for 30 seconds at room temperature, the 
cells were freed for 2 min to allow dehydration. The cells were then incubated for 5 to 
10 min with the staining solution at 37 °C, 5 % CO2 and the staining was stopped by 
washing the cells in 3 changes of distilled water. Stained cells were visualized under an 
inverted microscope, magnification 10x, and multinucleated cells with 3 or more nuclei 
were counted. The cells were stored at 4 °C for further investigations. 
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2.2.10 Growth inhibition assay 
 
MDA-MB-231 (15x104 cells/well), PC3 (23x104 cells/well) and U2OS (7x104 
cells/well) were seeded in triplicates in 6-well plates and allowed to attach for 2 days. 
Cells were then treated with the vehicle (absolute ethanol) or drug in increasing 
concentrations for 24 and 48 hours. Before treatment, cells of 3 wells (each well 
handled separately) were enzymatically detached, collected and counted using the Casy 
cell counter. The average count at this step was considered as the starting time 0 cell 
density for all vehicle and treated groups. At different time points, cells were 
enzymatically detached, collected, counted and the average cell density per treated 
group (n=3 wells/group) was compared to the average cell density of the vehicle group 
at that specific time point. The data are presented as mean ± SEM. 
 
2.2.11 Cell viability assay 
 
The MTS-test was used to determine the number of viable cells in culture. This method 
involves the CellTiter 96®AQueous One Solution Reagent (#G3580, Promega, 
Madison, WI, USA) composed of 1.90 mg/ml MTS and 300 µM PES in Dulbecco’s 
buffered saline, pH 6.0. OB (2x104 cells/well), RAW 264.7 (4x104 cells/well), MDA-
MB-231 (37x103 cells/well), PC3 (37x103 cells/well) and U2OS (25x103) were seeded 
in 96-well plate, 8 wells per groups, and allowed to attach for at least 1 hour. Thereafter, 
cells were submitted to the vehicle or drug in increasing concentrations for 6 to 48 
hours. Before termination, the cells were incubated with 20 µl of the CellTiter reagent 
for 2 hours and the absorbance was read at 490 nm with a Multiskan plate reader. The 
data were collected using Delta Soft3 software and the results are presented as a 
proportion of viable cells in the presence of pharmacological compound compared to 
the vehicle group. 
 
2.2.12 Cytoskeleton staining and apoptosis  
 
OB, OC and RAW 264.7 cells on coverslips were fixed with 3.7 % formaldehyde in 
PBS for 3 and 10 min, incubated with Alexa Fluor 488 conjugated phalloidin (0.165 µM 
in PBS) (#A12379, Molecular Probes, Invitrogen) for 30 min at room temperature 
followed by the DAPI reagent (0.1 µg/ml in PBS) (Sigma-Aldrich) for 10 min at 37 °C 
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and 5 % CO2. MDA-MB-231, PC3 and U2OS on coverslips were fixed for 3 and 10 
min with 3.7 % formaldehyde in PBS at room temperature, and then incubated with 0.1 
µg/ml of the DAPI reagent in PBS for 15 min at 37 °C, 5 % CO2. The coverslips were 
mounted onto microscope glass slides using fluorosave embedding medium, sealed with 
Fixogum rubber cement (Marabuwerke GmbH & Co.KG, Germany) and stored at 4 °C. 
Stained coverslips were examined under a fluorescence microscope using the triple 
band filter set DAPI/FITC/TRITC and a 40x objective with immersion oil. The 
cytoskeleton was examined on the basis of cell shape and F-actin organization using 
phalloidin labeling, while apoptotic cells were identified based on the condensation of 
chromatin and fragmentation of nuclei (apoptotic bodies) with DAPI staining. 
 
2.2.13 Study of cell transduction signaling 
 
2.2.13.1 Principle of ECL western blotting detection of proteins 
 
Enhanced chemiluminescence (ECL) western blotting is a light emitting, non-
radioactive method for detection of immobilized specific antigens, directly or indirectly 
with Horseradish peroxidase (HRP) labeled antibodies. Enhanced chemiluminescence is 
achieved by performing the oxidation of luminol (substrate in the ECL detection 
reagent) by the HRP (conjugated on the secondary antibody) in the presence of 
chemical enhancers such as phenols. The oxidized luminol then decays to the ground 
state by emitting a light with maximal intensity between 5 and 20 min and a half-life of 
approximately 60 min. The maximum light emission is at a wavelength of 428 nm and 
can be detected by a short exposure to blue-light sensitive autoradiograghic film 
(Hyperfilm ECL). 
This technique is widely used to detect and identify proteins that have been previously 
resolved on SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
and blotted onto a membrane. 
 
2.2.13.2 Cell culture and lysis 
 
RAW 264.7 cells were cultured on 6-well plates (Iwaki) in presence or absence of 50 
ng/ml rm RANKL for 5 to 6 days. The role of the cytokine was to allow differentiation 
of the monocyte-macrophage cell line into multinucleated cells. Following culture, cells 
were treated with the vehicle (ice cold absolute ethanol) or with the pharmacological 
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compound (1 µM BEA or 10 µM ENN) for different time points (1 min, 15 min, 1h, 
2h), then washed 3 times with ice cold PBS and submitted to lysis. Cells were lysed in 
lysis buffer (50 mM NaCl, 10 mM Tris-base, 1 % Triton X-100, pH 7.05) containing 
proteases and phosphatases inhibitors (50 mM NaF, 10 µg/ml Aprotinin, 10 µg/ml 
Leupeptin, 1 µg/ml Pepstatin, 2 mM Orthovanadate, 1mM PMSF), using 100 µl lysis 
buffer for 2 wells and cell scrapers to detached the cells from the wells. Lysed cells 
were then transferred into eppendorf tubes, sonicated on ice for 1 min to shear the DNA, 
vortexed every 2 min for 15 min and centrifuged at 4 °C, 15000 rpm for 15 min. The 
supernatant was collected and 5 µl of cell lysate was used for the protein assay while the 
rest was stored at –80 °C for further analyses. 
 
2.2.13.3 Protein assay 
 
The total sample protein content was assayed in a Greiner 96-well plate using the Bio-
Rad DC protein assay reagents kit (reagents A, B and S) (Bio-Rad Laboratories, 
Hercules, CA, USA). 5 µl of sample (cell lysate or BSA standard at different 
concentrations) was incubated with 25 µl solution A’ (mixture of reagent A + reagent S: 
for 1000 µl of reagent A, we needed 20 µl reagent S to obtain the solution A’) and 200 
µl reagent B. The plate was then gently vortexed and incubated for 15 min at room 
temperature. The absorbance was read at wavelength 690 nm, using a Labsystems 
Multiskan MS plate reader and data were processed using Delta Soft 3 software. 
Therefore, the standard curve was plotted automatically and the protein concentrations 
were read directly. Results are expressed as µg protein/µl cell lysate and represent the 
mean values from 2 replicates. 
 
2.2.13.4 Electrophoresis 
 
About 30 µg of proteins per sample were resolved on 10 % SDS-PAGE. The running 
gel was prepared and poured into a Bio-Rad mini-gel mould. The system was left at 
room temperature for at least 1 hour or overnight, to allow polymerization. Following, 
the stacking gel was prepared and overlaid on the running gel. The comb was inserted in 
there, to pre-set the wells into which the samples will be further deposited, and left at 
room temperature for 1 hour to allow polymerization. At the same time, the samples 
were being prepared by mixing with 1X and 4X sample buffers, cooking at 95 °C for 5 
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min, followed by a quick centrifugation. After polymerization of the stacking gel, the 
comb was gently removed and the wells washed 3 times with 1X running buffer. The 
system was then transferred in an electrophoresis tank (Mini Protean II Electrophoresis 
Cell) with 1X running buffer for running of the electrophoresis. Equal volumes of 
samples corresponding to equal amounts of proteins (30 µg/sample) were loaded into 
the wells. The cell lysate of a reference cancer cell line (A-431) was used as control for 
sufficient protein separation, as well as a molecular weight marker containing standard 
proteins with known molecular weights (SeeBlue Plus2 Prestained Standard, #LC5925, 
Invitrogen; or PageRuler Prestained Protein Ladder, #SM0671, Fermentas). The SDS 
included in the samples linearized the proteins, and conferred to them a negative charge. 
Therefore, they were allowed to migrate across the gel towards the anode only 
according to their weight. A current of 350 mV with a potential difference of 25 mA 
was applied until all samples reached the running gel. Thereafter, the proteins were 
submitted to a new current of 350 mV with a potential difference of 35 mA and 
migrated all along the running gel. The electrophoresis was termed finished when all 
samples had resolved until the level of the appropriate molecular weight markers. 
 
2.2.13.5 Transfer of proteins to nitrocellulose membrane 
 
Following electrophoresis, the gel with Proteins was carefully removed from the 
electrophoresis plates and immediately given on a filter paper, then covered with the 
nitrocellulose membrane and again with a second filter paper (creating a sandwich). The 
whole system was placed into a transfer tank (Mini Protean II Electrophoresis Transfer 
Cell) containing a magnetic stir bar and a cold transfer buffer was added. The proteins 
were transferred from the gel to the nitrocellulose membrane in cooling conditions, 
under a current of 100 V and 350 mA, on mixing with a magnetic stirrer for 1 hour. 
Thereafter, the nitrocellulose membrane was carefully marked with a pencil and stained 
with 0.20 % ponceau red to check for successful protein transfer and localization of 
proteins bands. 
 
2.2.13.6 Membrane blocking and antibody incubation 
 
The nitrocellulose membrane was rinsed 3 times with sterile water (to wash away the 
ponceau staining) and washed 5 min in TBS 1X (Tris buffer saline 1X) at room 
temperature on shaking. The blot was then incubated with the blocking solution (5 % 
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non fat dry milk in 0.1 % TBST) for 1 hour at room temperature on shaking. This step 
had the benefit to block non-specific sites of the antibody on the membrane. Following 
the blocking step, the blot was washed 3 times for 5 min each in 0.1 % TBST (Tris 
buffer saline tween 20) on shaking, and incubated for overnight at 4 °C with the primary 
antibody diluted 1:1000 (or otherwise stated) in 0.1 % TBST. Thereafter, the blot was 
washed 3 times for 5 min each in 0.1 % TBST on shaking, and incubated for 1 hour 
with the secondary antibody (anti-rabbit or anti-mouse IgG HRP conjugate) diluted 
1:5000 in 0.1 % TBST at room temperature. The detection was performed with an 
enhanced chemoluminescence detection kit. The membranes were stripped off bound 
antibodies after ECL detection and reprobed several times. It is important to point that 
during washing steps, the volume of wash buffer was as large as to completely 
submerge the blot and at any time, the blot was not allowed to dry out. 
The primary antibodies used were anti phospho Src-Tyr416 (1:1000, rabbit polyclonal, 
#2101, 60 kDa), anti phospho Akt-Ser 473 (1:1000, rabbit monoclonal, #4060, 60 kDa), 
anti phospho NF-κB p65-Ser536 (1:1000, rabbit monoclonal, #3033, 65 kDa), anti 
phospho-p38 MAPK Thr180/Tyr182 (1:1000, rabbit polyclonal, #9211, 43 kDa), anti 
caspase 3 (1:1000, rabbit polyclonal, #9662, 35 kDa) and anti cleaved PARP (1:1000, 
rabbit polyclonal, #9544, 89 kDa) from Cell Signaling, Inc (Beverly, MA, USA). Anti 
phospho p-44/42 MAPK Thr202/Tyr204 (1:1000, mouse monoclonal, #9106, 44/42 
kDa) was from New England Biolabs, Inc (Ipswich, MA, USA). Anti E-cadherin 
(1:2500, mouse monoclonal, #C20820, 120 kDa), anti FAK (1:1000, mouse 
monoclonal, #F15020, 125 kDa) and anti STAT3 (1:2500, mouse monoclonal, 
#S21320, 92 kDa) were purchased from Transduction Laboratories (Lexington, KY, 
USA). Anti PI3 kinase α (333) (1:1000, rabbit polyclonal, #sc-423, 85 kDa) was from 
Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA) and anti ß-actin (1:2000, mouse 
monoclonal, #A-2228, 42 kDa) from Sigma (St. Louis, MO, USA). The secondary 
antibodies anti-mouse IgG HRP-conjugate (#W4021) and anti-rabbit IgG HRP-
conjugate (#W4011) were from Promega (Madison, WI, USA). 
 
2.2.13.7 ECL detection of proteins 
 
Following incubation with the secondary antibody, the membrane was washed 3 times 
for 5 min each in 0.1 % TBST on shaking at room temperature. The membrane was 
further washed 2 times for 5 min each in TBS 1X to allow complete removal of the 
tween 20 from the membrane, as the latter could interfere with ECL reagents and 
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increase the background. The detection solution was prepared by mixing v/v detection 
reagent 1 and detection reagent 2 (both from GE Healthcare, UK), and the volume of 
this solution was calculated by multiplying the surface of the nitrocellulose membrane 
(in cm2) by 0.125 ml. Therefore, the blot was incubated with the detection solution for 1 
min at room temperature, then wrapped in a saran wrap and placed in the x-ray film 
cassette. The film was developed in the dark room under x-ray light and red safe light 
for short time period (20 seconds to 20 minutes) and following detection, the film was 
aligned with the blot to allow identification of molecular weight markers. 
 
2.2.13.8 Stripping and reprobing 
 
The complete removal of primary and secondary antibodies from the membrane had 
been made possible by stripping. After each ECL detection, the membrane was stored 
wet at 4 °C wrapped in a saran wrap. To perform the stripping, the membrane was 
washed 4 times for 5 min each in 0.1 % TBST at room temperature on shaking, 
followed by incubation for 30 min in the stripping buffer (containing ß-
mercaptoethanol) at 50 °C and 100 rpm. Thereafter, the blot was washed 6 times for 5 
min each in 0.1 % TBST at room temperature on shaking, and then blocked again in 5 
% non fat dry milk before reprobing with another antibody. 
 
2.2.13.9 Statistical analysis 
 
Data were analysed using one factor ANOVA (analysis of variance) incorporated in the 
StatView statistical program. All experiments were repeated at least 3 times. Statistical 
differences between groups were determined by Fisher’s LSD test. Significant 
differences are presented as *p<0.05, **p<0.01, ***p<0.001 compared to the control 
groups. 
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Abstract 
 
Beauvericin (BEA) and enniatins (ENN) are structurally related 
cyclohexadepsipeptides, produced by several strains of the fungi genus Fusarium, 
Beauveria, Polyporus and Paecilomyces that are known to contaminate food and feed. 
There is compelling evidence that fungal toxins may influence development and activity 
of osteoclasts (OC) and consequently, may be useful for the treatment of osteoporosis 
and bone tumours. To evaluate their effects on OC, we: 1- cocultured murine bone 
marrow cells with primary calvarial osteoblasts (OB) to generate OC, 2- assessed OC 
differentiation and viability using TRAP staining, 3- performed pit analyses of bovine 
bone slices, and 4- stained the cytoskeleton with alexa fluor 488 conjugated phalloidin. 
BEA inhibited bone resorption by disrupting the resorbing organelle (actin ring) of OC 
while ENN did not affect the actin ring structure and inhibited bone resorption directly 
by reducing the number of TRAP-positive OC. Moreover, BEA did not affect cell 
viability of mature OC, but induced apoptosis in OC likely by mechanisms involving 
ERK1/2 phosphorylation. Interestingly, ENN inhibited OC viability in a Src/Akt 
dependent manner and induced signal transduction pathways similar to that of PP2, a 
reference Src inhibitor. These results illustrate that BEA and ENN differentially 
regulate OC life span and activity. Therefore they could be potential candidates for the 
treatment of OC-induced bone loss used either alone or in combination. 
 
Key words: apoptosis, cyclohexadepsipeptides, ERK1/2, resorption, Src/Akt, viability 
 
1. Introduction 
 
Osteoclasts (OC) are multinucleated cells of the monocyte-macrophage lineage whose 
main and specific function is to regulate mineral homeostasis by resorbing the extensive 
surface of mainly trabecular bone [1,2]. For the proper development and maintenance of 
bone size, shape and integrity, the bone deposition (by OB) should be tightly balanced 
quantitatively, spatially and temporally with the bone resorption (by OC). A net 
increase in the rate of bone resorption with an insufficient increase in the rate of bone 
formation inevitably leads to osteoporosis with an increase risk of bone fractures, a state 
that is associated to many metabolic diseases; including Paget’s bone disease, various 
arthritis, diabetes mellitus [3]; and tumor osteolysis. Therefore, an identification of 
pharmacological compounds that could regulate bone cell generation and function 
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would be of great interest in the understanding and control of metabolic and metastatic 
bone diseases. 
Beauvericin (BEA) and enniatins (ENN) are well-known cyclohexadepsipeptide 
mycotoxins produced by Fusarium [4-8], Beauveria [9,10], paecilomyces [11] and 
polypovirus species [5]. They occur in fungi-contaminated grain samples at 
concentrations up to several mg/kg [8,12,13] and their toxicity to humans and animals 
may be underestimated, as to date there are no convincing evidence on the topic. 
However, they have been proven to be phytopathogenic, endowed with antibiotic 
[14,15], insecticidal [6,16,17], hydrophobic [18], ionophoric [19-21] and non mutagenic 
[22,15] properties, and have been reported to inhibit acyl-CoA: cholesterol transferase 
[18], the enzyme that catalyzes the conversion of cellular cholesterol and long chain 
fatty acyl-CoA to cholesteryl ester. Moreover, BEA is cytotoxic to several mammalian 
cell line models, including the murine P815 mastocytoma cells, Yac-1 lymphoma cells 
and EL-4 thymoma cells [23]; the rat mast cell like RBL-1 cells, the simian 
fibroblastoid CV-1 cells and the human IARC/BL 41 cells (from Burkitt’s lymphoma), 
HeLa cells (from cervical carcinoma) and Hep G2 cells (from hepatoma) [24,25], the 
human monocytic lymphoma cells U-937 and promyelocytic leukemia cells HL-60 both 
of myeloid origin [26], the human lymphoblastic leukemia cells (CCRF-CEM) [27] and 
the porcine kidney PK15 cells [28]. In particular, BEA induces programmed cell death 
similar to apoptosis and causes cytolysis accompanied by internucleosomal DNA 
fragmentation into 200 bp [23,25]. BEA induced cytotoxicity has been shown to be 
mediated by increased intracellular Ca2+ influx, either from internal stores [23,27], or by 
extracellular Ca2+ influx via the plasma membrane prior to the increased intracellular 
Ca2+ apoptotic effect [29]. ENN is cytotoxic to human cancer cells [30] and acts as 
potent inhibitor of drug efflux pumps [31,32]. 
Despite this huge amount of available information, their effect on the bone tissue is still 
far from being appreciated. Nakagawa et al. [33] reported that destruxins, related 
cyclodepsipeptides, inhibit bone resorption without affecting OC differentiation and 
survival, therefore raising the need of screening other cyclodepsipeptides, particularly 
BEA and ENN, for their antiresorptive effects. Thus in this study, we address the effect 
of two mycotoxins BEA and ENN on mouse bone cells OB and OC, and on the OC 
precursor cell line RAW 264.7 cells. 
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2. Materials and methods 
 
2.1. Animals and cells  
 
The animals used were BALB/c mice and New Zealand white rabbits. The cells used 
were OB isolated from newborn (1- to 2-days-old) mice; bone marrow cells extracted 
from femora and tibiae of at least 8-weeks-old mice or 5 days old rabbits, as well as the 
monocyte-macrophage cell line RAW 264.7. Cell cultures were maintained in a 
humidified atmosphere of 37 °C and 5 % CO2 in air. 
 
2.2. Drugs 
 
The substances used were 2 cyclohexadepsipeptides, BEA (#B-7510) and ENN (#E-
3643), both purchased as a desiccate from Sigma-Aldrich Chemie (Taufkirchen, 
Germany). ENN had a purity of approximately 96 %, a molecular weight of 681.5 g/mol 
and was composed of 3 % enniatin A, 20 % enniatin A1, 19 % enniatin B and 54 % 
enniatin B1. BEA was of 99 % purity with a molecular weight of 784 g/mol. The 
concentrations used ranged from 0.01 µM to 10 µM. The substances were dissolved in 
absolute ethanol to make stock solutions at 0.1 mM, 1 mM and 10 mM. The compounds 
are light sensitive; therefore, desiccates were stored dark at 4 °C and the stock solutions 
at – 80 °C. 
 
2.3. Chemicals 
 
Recombinant murine mouse RANKL was purchased from R&D systems (Minneapolis, 
MN, USA). The CellTiter96® AQueous One Solution Cell Proliferation reagents were 
from Promega (#G3580, Madison, WI, USA). ECL western blotting detection reagents 
were provided by Amersham Pharmacia Biotech (Aylesburg, UK). FluorSaveTM reagent 
was from Calbiochem (San Diego, USA). Alexa-488-conjugated Phalloidin was 
purchased from Molecular probes (#A12379, Leiden, Netherlands). DAPI (4,6-diamino-
2-phenyl-indoldihydrochloride), ponceau red, toluidine blue, naphtol AS-MX-
phosphate, fast red violet salt and collagenase type IV (#C9891) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 37 % acrylamide, TEMED and DC protein assay 
reagent kit (reagents A, B and S) were from Bio-Rad (Hercules, CA, USA). The 
primary antibodies anti-phospho Akt-Ser473 (rabbit monoclonal, #4060, 60 kDa), anti-
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Akt (rabbit polyclonal, #9272, 60 kDa), anti-phospho Src-Tyr416 (rabbit polyclonal, 
#2101, 60 kDa), anti-phospho NF-κB p65-Ser536 (rabbit monoclonal, #3033, 65 kDa), 
anti-Non phospho Src-Tyr416 (mouse monoclonal, #2102, 60 kDa), anti-phospho-p38 
MAPK Thr180/Tyr182 (rabbit polyclonal, #9211, 43 kDa), anti-p38 MAPK (rabbit 
polyclonal, #9212, 43 kDa) were from Cell Signaling, Inc (Beverly, MA, USA). Anti-
phospho p-44/42 MAPK Thr202/Tyr204 (mouse monoclonal, #9106, 44/42 kDa) was 
purchased from New England Biolabs, Inc (Ipswich, MA, USA). Anti-PI3 kinase α 
(333) (rabbit polyclonal, #sc-423, 85 kDa) was purchased from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA, USA) and anti-ß-actin (mouse monoclonal, #A-
2228, 42 kDa) from Sigma (St. Louis, MO, USA). The secondary antibodies anti-mouse 
IgG HRP-conjugate (# W4021) and anti-rabbit IgG HRP-conjugate (#W4011) were 
from Promega (Madison, WI, USA).  
 
2.4. Preparation of osteoblasts 
 
Primary cultures of mouse OB cells were obtained by sequential collagenase/dispase 
digestion from calvariae of newborn mice. OB were passaged once, grown till 
confluency again and then stored in liquid nitrogen until experiments were performed. 
Mouse OB were seeded at a density of 2x106 cells/60 cm2 in α-modification of the 
minimal essential medium (α-MEM) supplemented with 10 % heat inactivated FCS 
(Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany), 100 U/ml penicillin (Life 
Technologies Inc. Grand Island, USA), and 100 µg/ml streptomycin (Life Technologies 
Inc. Grand Island, USA) and grown until confluency (approx. 3 - 4 days). 
 
2.5. Preparation of mouse osteoclasts 
 
Bone marrow cells from the femora and tibiae of 6- to 8-weeks-old mice were cultured 
(density of approx. 500 000 cells/cm2) together with primary OB isolated from calvariae 
of newborn mice (density of 30 000 cells/cm2) on plastics, coverslips or bone slices, 
under osteoclastogenic conditions (1 nM 1,25-(OH)2-Vitamin D3 (Hoffmann-La Roche, 
Basel, Switzerland) and 1 µM PGE2 (Cayman, USA)) in α-MEM containing 10 % FCS, 
100 U/ml penicillin, and 100 µg/ml streptomycin. For differentiation studies, different 
concentrations of BEA, ENN, or the vehicle (absolute ethanol, final concentration in 
cultures 1 ‰ v/v) were applied immediately (day 0) and/or at day 2 and 4 with medium 
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change. Pre-fusion OC were prepared by incubating OB and bone marrow cells together 
for 4 days under osteclastogenic conditions with one medium refreshment at day 2. For 
viability experiments [33], primary precursors (OB and bone marrow cells) were 
cocultured and allowed to differentiate within 5 days into multinucleated OC. 
Afterwards, the OB layer was carefully removed by washing with warm phosphate-
buffered saline (PBS) without Ca2+/Mg2+ and the remaining OC culture of about 95 % 
purity was incubated with 1-10 µM BEA or ENN for 2, 6 and 12 hours. 
 
2.6. Preparation of rabbit osteoclasts 
 
OC were isolated from the long bones of 5 days-old New Zealand white rabbits. They 
were transferred onto plastics, coverslips or bone specimens and first incubated for 2 
hours in α-MEM (with 10 % FCS, 100 U/ml penicillin and 100 µg/ml streptomycin), 
then rinsed to remove most of the contaminating cells and thereafter incubated for 24 
hours in the presence or absence of different concentrations of the test compounds. 
 
2.7. Tartrate Resistant Acid Phosphatase (TRAP) staining 
 
After treatment, cells on coverslips or plastics were fixed with 3.7 % formaldehyde 
(Sigma-Aldrich, St. Louis, MO, USA) in PBS for 13 min at room temperature, and 
incubated in the TRAP buffer containing 40 mM sodium acetate (pH 5) and 10 mM 
sodium tartrate for 30 min at 37 °C, 5 % CO2. Thereafter, cells were permeabilized with 
ethanol/acetone (v/v) and stained for activity of TRAP with a solution containing 
dimethyl formamide, naphthol AS-MX phosphate and fast red violet salt for 5 to 10 
min. TRAP-positive multinucleated cells with 3 or more nuclei were counted. 
 
2.8. Toluidine blue staining 
 
Attached OC were removed from bone slices by 15 min sonication in 70 % isopropanol, 
stained with 0.1 % toluidine blue, washed in distilled water, and stored dry until pit area 
measurement. The areas of OC resorption lacunae were measured using a Nikon 
Optiphot microscope with a 10x/0.30 NA objective under oblique illumination. Six 
photographs per bone slice were taken randomly, digitized using Adobe Photoshop and 
processed using NIH-Image 6.0 and Microsoft Excel. 
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2.9. Cell viability assay 
 
The MTS-test (CellTiter 96®AQueous One Solution Reagent) was used to determine the 
number of viable cells in culture. The test was performed by seeding 50 µl suspension 
of OB at a density of 2x104/well or RAW 264.7 cells at 4x104/well (maintained in α-
MEM with 2 mmol/l glutamax, 10 % heat inactivated FCS, 100 U/ml penicillin and 100 
µg/ml streptomycin) in a 96-well culture plate (Iwaki, Asahi Techno Glass, Japan). The 
cells were first incubated for 1 hour to allow attachment on the plastic surface. 
Thereafter, another 50 µl medium containing different concentrations of the test 
compounds were added to each well and the cells were incubated for another 6 to 24 
hours. 15 µl of the CellTiter reagent was added in each well for the last 2 hours of 
incubation and the absorbance was read at 490 nm with a Labsystems Multiskan MS 
plate reader (Labsystems Mult 45139, Finland). The data were collected using Delta 
Soft3 software. The results are presented as a proportion of viable cells in the presence 
of BEA or ENN compared to untreated cells (vehicle group). 
 
2.10. Cytoskeleton staining and apoptosis 
 
(OB and bone marrow cells), rabbit OC, OB (2 millions/6-well plate) and RAW 264.7 
cells (4 millions/6-well plate) were seeded on coverslips and incubated for 24 hours. 
Afterwards, the cells were treated with the vehicle or with the pharmacological 
compound (BEA or ENN) for 6, 12 or 24 hours. Pre-fusion OC obtained at day 4, were 
further incubated for 24 hours with BEA or ENN. After treatment, the cells (coverslips) 
were fixed with 3.7 % formaldehyde in PBS for 13 min, incubated with Alexa 488-
conjugated phalloidin (0.165 µM) in PBS for 30 min at room temperature followed by 
the DAPI reagent (0.1 µg/ml) for 10 minu at 37 °C, 5 % CO2. The coverslips were 
mounted onto microscopes glass slides (Menzel-Glaser, Germany) using fluorosave 
embedding medium, sealed with Fixogum rubber cement (Marabuwerke GmbH & 
Co.KG, Germany) and stored at 4 °C. Stained coverslips were examined under a 
fluorescence microscope (Optiphot2-UD, Nikon, Japan) using the triple band filterset 
DAPI/FITC/TRITC and a 40x objective with immersion oil. The cytoskeleton was 
examined on the basis of cell shape and F-actin organization using the phalloidin 
labeling, and apoptotic cells were identified based on nuclear fragmentation (apoptotic 
bodies) and condensation of chromatin (DAPI staining). 
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2.11. Western Blotting experiments 
 
Mouse OC from primary precursors (OB and bone marrow cells) or OC derived from 
the monocyte-macrophage cell line RAW 264.7 stimulated with rmRANKL, were 
treated with the vehicle, BEA (1 µM) or ENN (10 µM) in starvation medium 
(containing only 0.5 % heat inactivated FCS) at different time points 0, 1, 15, 60 and 
120 min. In some experiments, cells were treated with the reference Src kinase inhibitor 
PP2 (Alexis Biochemicals, Lausen, Switzerland) or the reference MAPK inhibitor 
PD98059 (Calbiochem, San Diego, USA) prior to the addition of BEA or ENN 
respectively. After treatment, cells were washed several times with ice-cold PBS and 
lysed in lysis buffer (50 mM NaCl, 10 mM Tris-base, 1 % Triton X-100, pH 7.05) 
containing several inhibitors of proteases and phosphatases (50 mM NaF, 10 µg/ml 
Aprotinin, 10 µg/ml Leupeptin, 1 µg/ml Pepstatin, 2 mM Orthovanadate, 1mM PMSF). 
About 30 µg of proteins per sample were resolved on 10 % SDS-PAGE according to 
their molecular weight, electrotransferred onto a 0.45 µm nitrocellulose membrane 
(Whatman GmbH, Dassel, Germany), blocked for one hour in 5 % non fat dry milk in 
Tris Buffer Saline Tween 0.1 % (TBST) and incubated overnight at 4 °C with the 
primary antibody (1:1000 in TBST 0.1 %). Afterwards, the proteins were incubated for 
one hour with the secondary antibody (HRP-conjugated anti-mouse or anti-rabbit) 
(1:5000 in TBST 0.1 %) and the detection was performed with an enhanced 
chemoluminescence detection kit. The membranes were stripped and reprobed several 
times. 
 
2.11. Statistical significance 
 
The data were processed using one factor ANOVA (analysis of variance) incorporated 
in the StatView statistical program. All experiments were repeated at least 3 times. 
Statistical differences between groups were determined by Fisher’s LSD test. 
Significant differences are presented as *p<0.05, **p<0.01, ***p<0.001 versus 
untreated groups (vehicle). 
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3. Results 
 
3.1. BEA and ENN inhibit OC differentiation and bone resorption 
 
In our first series of experiments, we found that BEA and ENN inhibit OC 
differentiation and bone resorption. Primary precursors (OB and bone marrow cells) 
were seeded on bone slices and treated with BEA or ENN in increasing concentrations 
(0.1-10 µM). We observed a dose-dependent inhibition of bone resorption by BEA and 
ENN (Fig.1). However, BEA was more potent as compared to ENN given that the 
inhibition of bone resorption with 0.1 µM BEA was significantly reduced versus control 
(p<0.01) compared to that of ENN 0.1 µM (Fig.1). These results were confirmed in 
rabbit OC where BEA and ENN also inhibited bone resorption dose-dependently (Fig. 
2) and again, 0.01 µM BEA was more potent in inhibiting bone resorption compared to 
ENN 0.01 µM. Next, we sought to determine the effect of these 2 compounds on 
different stages of OC differentiation and consequently on bone resorption. In a 
coculture system, OB stimulated with vitamin D3 and PGE2 produce several factors 
including M-CSF and RANKL, which allow bone marrow cells to differentiate within 4 
days into pre- fusion OC and to terminally differentiate after 5 days in multinucleated 
OC with bone resorbing activity. We carried our coculture system (OB and bone 
marrow cells) on bone slices and treated starting from day 0, from day 2 or from day 4. 
At lower concentration (0.1 µM), BEA did not inhibit bone resorption (addition from 
day 4) (Fig. 3A) as compared to the control. However, the same concentration of BEA 
(0.1 µM) significantly inhibited bone resorption when added from day 0 (p<0.05) or 
from day 2, by inhibiting differentiation of bone marrow cells into OC precursors. From 
1-10 µM BEA, we observed a dose-dependent and time-dependent inhibition of bone 
resorption, confirming the fact that BEA does not only inhibit bone resorption per se, 
but also inhibits differentiation of bone marrow cells in bone resorbing cells (Fig. 3A). 
With regard to ENN, a lower concentration (0.1 µM) did not significantly affect OC 
differentiation (when added from day 0 or from day 2), nor did it affect bone resorption 
(when added from day 4) (Fig. 3B). The moderate concentration 1 µM inhibited OC 
differentiation (when added from day 0) (p<0.001) without affecting bone resorption. 
Finally, at 10 µM, both, differentiation in OC and bone resorption were significantly 
inhibited (p<0.001). Taken together, these data suggest that BEA and ENN dose-
dependently inhibit OC differentiation and bone resorption. However, at moderate 
concentrations (1 µM), BEA affects both OC differentiation from bone marrow 
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precursors and bone resorption, while ENN only affects OC differentiation from bone 
marrow precursors, but not bone resorption per se. 
 
3.2. BEA and ENN inhibit differentiation of bone marrow precursors, but not of 
pre-fusion OC, into TRAP-positive multinucleated OC 
 
To further confirm the effects of both compounds on OC differentiation, we cultured 
primary precursors (OB and bone marrow cells) on coverslips and allowed them to 
differentiate into multinucleated OC upon increasing concentrations (0.1-10 µM) of 
BEA or ENN. The TRAP-staining was performed at the end of the culture (Fig. 4A) and 
we observed a dose-dependent inhibition of TRAP+ cells, showing a significant effect 
already at 1 µM with BEA (p<0.001) and 10 µM with ENN (p<0.001). However, these 
concentrations were higher than those that inhibited bone resorption in the pit assay 
conditions (Fig. 1). Indeed, we observed inhibition of bone resorption at 10 times much 
lower concentrations, 0.1 µM for BEA and 1 µM for ENN. To evaluate the effect of the 
compounds on pre-fusion OC, we cocultured primary precursors (OB and bone marrow 
cells) for 4 days to allow them to differentiate in pre-fusion OC (Fig. 4B). We then 
treated these pre-fusion OC with 1 and 10 µM BEA or ENN for 24 hours, followed by 
TRAP staining. Interestingly, at 1 µM, BEA and ENN did not affect differentiation into 
multinucleated OC. However, at 10 µM, they inhibited OC differentiation (p<0.001), 
with BEA being more potent compared to ENN (p<0.05). Taken together, these results 
suggest that first: BEA and ENN inhibit OC differentiation from bone marrow 
precursors dose-dependently (Fig. 4A), second: At concentrations equal and lower than 
1 µM, BEA and ENN have no effect on OC differentiation from pre-fusion OC (Fig. 
4B), third: At 1 µM, BEA affects bone resorption from pre-fusion OC (Fig. 3A, addition 
BEA 1 µM from day 4), but not OC differentiation (Fig. 4B) while at the same 
concentration (1 µM) ENN has no effect both on bone resorption (Fig. 3B, addition 
ENN 1 µM from day 4) and OC differentiation (Fig. 4B). 
 
3.3. Effects of BEA and ENN on the cytoskeleton and apoptosis of OC 
 
Polarization of OC is an essential step in the initiation of bone resorption with actin ring 
being the essential organelle of a resorbing OC. We next evaluated whether or not an 
effect of BEA or ENN on actin ring formation could be responsible for the inhibition of 
bone resorption. We cocultured precursors on coverslips for 4 days and then performed 
Achievement of the study 
 
55 
the treatment with 1-10 µM BEA or ENN for 24 hours, followed by phalloidin and 
DAPI nucleic acid staining. 9.3 % of OC in the control group (Fig. 5B) showed a well-
developed actin ring (Fig. 5Aa) with no sign of apoptosis (fragmentation and/or 
condensation of nuclei). At 1 µM BEA, the number of OC bearing an actin ring (4.7 % 
OC with actin ring, Fig. 5B) was reduced by half compared to the control and the actin 
ring was more present as dense patches spread around the cell (Fig. 5Ab). At the same 
concentration (1 µM), ENN increased the number of OC with well-defined actin ring 
(Fig. 5Ac) to 12.4 % (Fig. 5B). However, there was no significant differences in the 
number of apoptotic cells in both BEA 1 µM and ENN 1 µM as compared to the control 
(Fig. 5C). At a higher concentration (10 µM), the cytoskeleton was not organized as an 
actin ring in BEA treated-OC (Fig. 5B, p<0.05 compared to the control). In ENN 
treated-OC, the actin appeared as dense patches around the cells and throughout the 
cytoplasm with slightly reduced OC number bearing an actin ring (7.1 % OC with actin 
ring, Fig. 5B). Interestingly, at this higher concentration (10 µM), BEA significantly 
induced apoptosis (p<0.05 compared to the untreated control and to ENN 10 µM) 
whereas ENN had no effect (Fig. 5C). Collectively, these data suggest that BEA 
primarily affects bone resorption by disrupting the resorbing organelle (actin ring) of 
OC and later on, due to the reduction of TRAP+ multinucleated cells, while ENN has 
no effect on the actin ring structure and therefore affects bone resorption due to the 
reduction of TRAP+ multinucleated OC. Moreover, BEA is apoptotic at higher 
concentrations (10 µM) whereas ENN is not at all apoptotic. 
 
3.4. ENN, but not BEA, affects OC viability 
 
At this stage, it was interesting for us to determine the effects of our drugs on OC 
viability. The experiment was performed as described in the materials and methods 
section. After 2 and 6 hours, neither BEA, nor ENN affected OC viability (Fig. 6A). 
Surprisingly, after 12 hours incubation, ENN dose-dependently decreased OC viability 
by half as compared to the control (p<0.01 and p<0.001 respectively for 1 µM and 10 
µM ENN) while BEA had no effect at all. Taken together, these data suggest that ENN, 
but not BEA affects the OC viability. 
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3.5. BEA and ENN have more effect on the viability of RAW 264.7 cells than OB 
 
At this point, it was necessary to assess the effect of the cyclodepsipeptides on the 
viability of OB to make sure that the inhibiting effect observed in OC derived from 
cocultures was not coming from OB. To do so, we submitted OB to increasing 
concentrations (0.1-10 µM) of BEA or ENN for 6 to 24 hours and the cell survival rate 
was determined by the MTS-test method. BEA and ENN affected OB viability (Fig. 
6B) only at a higher concentration (10 µM) and at all time points (6-24 hours), but with 
a more significant effect of BEA (p<0.001) than ENN (p<0.01 at 6 and 24 h, p<0.05 at 
12 h) when compared to the control. RAW 264.7 is a monocyte-macrophage cell line 
that can differentiate in OC upon stimulation with RANKL and is therefore considered 
to be an OC precursor. We assessed the effect of BEA and ENN on the viability of these 
RAW 264.7 cells and both compounds exerted significant inhibitory effects, even at a 
lower concentration (0.1 µM) and at all time points; again with BEA being more potent 
(Fig. 6B). Moreover, RAW 264.7 cells were more sensitive to both BEA and ENN 
when compared to OB. 
 
3.6. BEA and ENN induced apoptosis in RAW 264.7 cells and OB 
 
To characterize BEA and ENN-induced growth inhibition, morphological changes of 
OC precursors (OB and RAW 264.7 cells) were examined using the DAPI staining. The 
nuclear morphology of the control and treated cells was compared on the basis of 
nuclear fragmentation and condensation of chromatin. At lower concentrations (0.1 and 
1 µM), neither BEA, nor ENN induced apoptosis in RAW 264.7 cells or OB as 
compared to the control (Fig. 7). However, at a higher concentration (10 µM), BEA 
significantly induced apoptosis in RAW 264.7 cells (p<0.001 at all time points) and in 
OB (p<0.05 at 6 h, p<0.001 at 12 and 24 h). At the same concentration (10 µM), ENN 
also significantly induced apoptosis in RAW 264.7 cells (p<0.001 at 12 and 24 h), but at 
a lower extent in OB (p<0.05 at 12 and 24 h). To summarize, BEA and ENN induced 
apoptosis in RAW 264.7 cells and in OB only at higher concentrations, with more effect 
on RAW 264.7 cells as compared to OB and with a more apoptotic effect of BEA as 
compared to ENN. 
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3.7. Signal transduction of BEA and ENN 
 
3.7.1. Using RAW 264.7 cells 
 
To understand the molecular mechanisms underlying such biological responses, we first 
used the monocyte-macrophage cell line RAW 264.7 as an OC model. RAW 264.7 cells 
were cultured for 6 days in the presence of 50 ng/ml rmRANKL to generate OC (Fig. 
8). The latter were then treated with BEA 1 µM (Fig. 8A) or ENN 10 µM (Fig. 8B) for 
different time points, lysed, resolved on SDS-PAGE and the western blot was 
performed to target phosphorylated and total proteins. Actin served as control for equal 
loading. The MAPK pathway has been implicated in cell proliferation, differentiation 
and survival. In BEA treated RAW 264.7-derived OC, the MAPK pathway was affected 
with activation of ERK1/2 and p38 MAPK. Moreover, we observed a slight 
upregulation of Akt. On the other hand, ENN affected the MAPK pathway by a 
dephosphorylation of ERK1/2 at 1 and 15 min of treatment, followed by its 
rephosphorylation after 1 and 2 hours. Akt and p38 MAPK were upregulated with time, 
unlike Src that was downregulated. Taken together, these data suggest that BEA and 
ENN both affect the MAPK and Akt pathways in RAW 264.7-derived OC. 
 
3.7.2. Using a Coculture system 
 
To clarify these findings, we used the coculture system as described in materials and 
methods. Fig. 9 (A and D) shows the signal transduction pathways of BEA 1 µM in 
coculture-derived OC. We observed a time-dependent upregulation of Src with maximal 
levels after 1 and 2 hours. This result was confirmed by the reference Src inhibitor PP2, 
which prevented upregulation of Src when applied 15 min or 1 hour prior to the 
treatment with BEA. PI3 kinase was affected neither by BEA, nor when PP2 was 
applied before BEA implicating that PI3 kinase is either upstream of Src, or is 
independent of the Src pathway. Akt was downregulated after 1 and 15 min treatment 
with BEA and upregulated again after 1 and 2 hours. Interestingly, PP2 prevented 
upregulation of phospho Akt when applied 1 hour prior to BEA treatment indicating 
that Akt is downstream of Src. BEA affected the MAPK pathway by upregulating p38 
MAPK and slightly upregulating phospho ERK1/2. Surprisingly, PP2 did not prevent 
upregulation of neither ERK1/2, nor p38 MAPK indicating that BEA activates the 
MAPK pathway in a Src-independent manner. Finally, the NFκB pathway was 
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downregulated by BEA and was not affected by a pretreatment with PP2 indicating that 
BEA downregulates NFκB independently of Src. To summarize, BEA acts as a Src 
activator, promotes a Src-dependent activation of Akt, upregulates the MAPK pathway 
independently of Src and downregulates the NFκB pathway independently of Src. 
Fig. 9 (B and E) shows the signal transduction pathways of ENN 10 µM in coculture-
derived OC. Likewise BEA; ENN affected the MAPK pathway by upregulating both 
ERK1/2 and p38 MAPK. Interestingly, the reference MAPK/ERK kinase (MEK) 
inhibitor PD98059 alone did not affect ERK1/2. This could be due to our experimental 
setting which involved starvation of the cells 15 min prior to and during treatment. 
Moreover, PD98059 did not prevent up-regulation of the MAPK pathway by ENN, 
indicating that ENN affects the MAPK pathway in a MEK-independent manner. Again, 
we observed no change in PI3 kinase levels neither with ENN alone, nor when 
following pretreatment with PD98059. Therefore, PI3 kinase is upstream or 
independent of the MAPK pathway. On the other hand, ENN downregulated Src more 
efficiently after 15 min, and when applied prior to ENN, PD98059 did not prevent ENN 
from downregulating Src. Akt levels increased after 1 and 15 min treatment with ENN 
and decreased again after 1 and 2 hours. PD98059 had no effect on Akt and did not 
prevent ENN from upregulating Akt after 1 and 15 min. Finally, ENN downregulated 
NFκB after 1 and 2 hours and the MEK inhibitor PD98059 did not affect the regulation 
of NFκB when applied before ENN. In a previous study, Recchia et al. [34] used potent 
and selective c-Src inhibitors (pyrrolopyrimidine derivatives) to investigate the 
functional and molecular consequences of inhibited c-Src tyrosine kinase activity in 
OC, and reported that these small pyrrolopyrimidine derivatives impaired OC function 
and induced cell damage suggesting apoptosis in vivo and in vitro by mechanisms likely 
involving selective sustained ERK1/2 phosphorylation. The fact that ENN both 
downregulated Src and phosphorylated ERK1/2, led us to hypothesize that ENN might 
be a Src inhibitor. To address this hypothesis, we used PP2, a reference Src inhibitor 
along side with ENN in the same experimental conditions (Fig. 9C). As expected, PP2, 
just like ENN, inhibited Src and Akt, upregulated the MAPK pathway and 
downregulated the NFκB pathway. Altogether, ENN that behaves like a Src kinase 
inhibitor, upregulates the MAPK pathway independently of MEK and finally 
downregulates the NFκB pathway in a MEK-independent manner. 
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4. Discussion 
 
In this study, we observed that first: BEA and ENN dose-dependently inhibited OC 
differentiation (Fig. 4A) and bone resorption (Fig. 1) from bone marrow precursors, 
second: at concentrations equal to 1 µM, BEA affected both OC differentiation from 
bone marrow precursors and bone resorption (Fig. 3A) while ENN affected only OC 
differentiation from bone marrow precursors, but not bone resorption per se (Fig. 3B), 
third: at concentrations equal and lower than 1 µM, BEA and ENN had no effect on OC 
differentiation from pre-fusion OC (Fig. 4B), fourth: at 1 µM, BEA affected bone 
resorption from pre-fusion OC (Fig. 3A, addition BEA 1 µM from day 4), but not OC 
differentiation (Fig. 4B) while at the same concentration (1 µM) ENN had no effect 
both in bone resorption (Fig. 3B, addition ENN 1 µM from day 4) and OC 
differentiation (Fig. 4B) from pre-fusion OC. It was obvious that BEA and ENN might 
both affect bone resorption through different mechanisms. With regard to ENN, the 
effect on OC differentiation was correlating with an effect on bone resorption 
suggesting that ENN may inhibit bone resorption directly by reducing the number of 
TRAP+ multinucleated cells. Opposed to ENN, the behaviour of BEA was puzzling. 
Indeed, OC differentiation was not affected at concentrations (BEA 1 µM, Fig. 4B) that 
inhibited pit formation (Fig. 3A, addition BEA 1 µM from day 4). This phenomenon 
has been previously reported in related cyclodepsipeptides dextruxins [33], where the 
latter were found to inhibit pit formation without affecting OC differentiation and 
survival. Moreover, the authors concluded that dextruxins inhibited bone resorption by 
specifically affecting the bone-resorbing function (actin rings) of OC. To verify that 
BEA might be acting by the same mechanism, we performed the cytoskeleton staining 
of OC treated with BEA or ENN. We confirmed that BEA, like dextruxins [33] 
primarily affected bone resorption by disrupting the resorbing organelles (actin rings) of 
OC and later on due to the reduction of TRAP+ multinucleated cells, while ENN had no 
effect on the actin ring structures and therefore affected bone resorption by directly 
reducing the number of TRAP multinucleated OC. 
The DAPI staining of BEA (10 µM) treated OC presented signs of apoptosis with 
fragmentation and/or condensation of nuclei. This result is consistent with previous 
studies where BEA has been reported to be cytotoxic to several mammalian cell line 
models [23-28]. Moreover, BEA was shown to induce programmed cell death similar to 
apoptosis and to cause cytolysis accompanied with internucleosomal DNA 
fragmentation into 200 bp [23,25]. Interestingly, ENN treated-OC presented no 
Achievement of the study 
 
60  
significant signs of apoptosis as compared to the control. However, in 2007, 
Dornetshuber et al. [30] reported that while short-term exposure (up to 8 hours) to ENN 
at nanomolar concentrations slightly, but significantly stimulated cell proliferation, it 
showed profound apoptosis-inducing effects, especially against various human cancer 
cell types at low micromolar concentrations (already after 24 hours of treatment). In our 
experimental setting, we used micro molar concentrations (1-10 µM) and comparable 
exposure time (24 hours). Features specific to the different cells lines we have used 
could explain the discrepancy of our results. Furthermore, we performed the apoptosis 
experiments using pre-fusion OC and not fully mature OC. Therefore we cannot 
exclude the possibility that ENN can induce apoptosis in mature OC. 
In addition to their similar effects on bone resorption, BEA, calcitonin (a powerful 
inhibitor of OC activity that exerts a rapid, transient, and reversible inhibition of bone 
resorption [35]) and dextruxins were found to have another common feature. Indeed, in 
our series of experiments, we observed that the viability of OC was not affected at all by 
BEA, one more feature that brings it closer to dextruxins, which are related 
cyclodepsipeptides previously reported to have no effect on the survival of OC [33]. 
Unlike BEA and dextruxins, ENN dose-dependently inhibited OC viability after 12 
hours. However, the reversibility of the effects of BEA or ENN on bone resorption has 
not been investigated in this study. 
The effects of both mycotoxins, especially ENN, on the induction of apoptosis and 
reduction of cell viability of OB were not as striking as on RAW 264.7 cells. 
Osteoporosis is a disease of the bone tissue that results from an imbalance between 
osteoclastic bone resorption and osteoblastic bone formation. If normal function is to be 
regained, substances of therapeutic interest should have little or no effect on OB. In this 
regard, Plotkin et al. [36] reported that the therapeutic efficacy of bisphosphonates or 
calcitonin in diseases such as glucocorticoid-induced osteoporosis might be due, at least 
in part, to their ability to prevent osteocyte and OB apoptosis. However, it has recently 
been demonstrated [37] that higher concentrations of alendronate and zoledronate were 
cytotoxic for OB, decreasing cell viability after 72 h, and this is consistent with our 
observations. The sensitivity of RAW 264.7 cells to BEA or ENN further supports the 
observation that these mycotoxins have an effect on OC precursors and are consistent 
with the observations of Tomoda et al. [18] who reported BEA and ENN to exert 
cytotoxic activities in J774 macrophages and to inhibit acyl-CoA: cholesterol 
transferase (ACAT) activity with BEA being the most potent inhibitor of microbial 
origin. 
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We have investigated the molecular signal transduction pathways of BEA and ENN in 
RAW 264.7 cells stimulated with the RANK-ligand to differentiate in OC, and in OC 
generated from cocultures. The proto-oncogene c-Src plays an essential role in bone 
remodeling, as deletion of the c-Src gene in transgenic mice by homologous 
recombination leads to osteopetrosis and impaired OC function [38]. Src can be 
activated downstream from RANK [39], a member of the tumor necrosis factor receptor 
superfamily that is involved in OC formation and survival, as well as in OC and 
dendritic cell function [40-43]. 
We have demonstrated that ENN reduced Src phosphorylation both in RAW 264.7 and 
coculture derived OC, which was consistent with the inhibition of bone resorption 
observed with this substance. The role of c-Src in OC differentiation has been 
controversial. It has been demonstrated that the number of TRAP+ OC was as higher in 
the Src-/- mice as in the wild type, although these OC were dysfunctional and unable to 
resorb the bone [44]. However, a reduction of TRAP+ cells following Src inhibition has 
been recently reported [34], indicating a novel role of c-Src in modulating OC 
differentiation. ENN inhibited bone resorption by reducing the number of TRAP+ OC 
rather than affecting the bone resorbing organelles (actin rings). The downregulation of 
c-Src observed here is in agreement with previous observations [34] and further 
supports a role of c-Src in OC differentiation. Opposed to ENN, BEA upregulated Src 
in OC. PP2, a reference Src inhibitor, prevented BEA from upregulating Src, 
confirming that BEA inhibits bone resorption independently of Src. 
Expression of a c-Src molecule truncated at amino acid 251 (Src251), lacking the kinase 
domain, induces osteopetrosis in wild type and Src+/- mice and worsens osteopetrosis in 
Src-/- mice by a novel mechanism not seen in Src-/- mice, consisting in an increase in OC 
apoptosis [45]. Expression of this Src251 molecule was associated with decreased Akt 
kinase activity and decreased OC survival in response to the RANK-ligand. In our 
study, ENN dose-dependently inhibited OC survival, correlating with down regulation 
of Src and Akt while BEA did not affect OC survival likely due to the Src/Akt up-
regulation. 
P38 MAPK is required for inducing OC differentiation, but without affecting neither the 
survival, nor the bone resorbing function of OC induced by RANKL [46]. However, c-
Src inhibition slightly stabilizes p38 MAPK as suggested by the reduction of phospho-
p38 in control versus inhibitor-treated OC [34]. These cyclodepsipeptides have in here 
been proven to phosphorylate p38 MAPK in OC, although independently of Src and 
their effects on cell survival. 
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The activation of the transcription factor NF-κB seems to play a crucial role in OC 
differentiation. This transcription factor is present as a complex with the inhibitory 
subunit IκB in unstimulated cells. Activation of NF-κB is controlled by sequential 
phosphorylation, ubiquitination, and degradation of its inhibitory subunit, IκB. Yet, 
ERK and NF-κB regulate different aspects of OC activation: ERK is responsible for OC 
survival whereas NF-κB regulates OC activation for bone resorption [47]. BEA and 
ENN both downregulated NF-κB, consistent with their inhibition of bone resorption. 
BEA did not affect the viability of OC, although we noticed a slight phosphorylation of 
ERK1/2. Meanwhile, BEA induced apoptosis in OC. A role of ERK1/2 in cell death has 
been previously reported. ERK1/2 activation mediates apoptosis after DNA damage in a 
p53 independent manner [48]. Moreover, small pyrollopyrimidine derivatives impair 
OC function and induce cell damage suggestive of apoptosis in vivo and in vitro by 
mechanisms involving selective sustained ERK1/2 phosphorylation [34]. Therefore, we 
believe that the phosphorylation of ERK1/2 following BEA treatment in OC, mediated 
apoptosis observed in this cells rather than their survival. ENN also upregulated 
ERK1/2, but without inducing apoptosis in OC. However, this up-regulation of ERK1/2 
may not mediate cell survival considering that ENN has been proven to inhibit cell 
survival. Interestingly, the reference MEK inhibitor PD98059 failed to prevent 
upregulation of ERK1/2 when applied before ENN suggesting that ENN upregulated 
ERK1/2 independently of MEK. Further analyses should be carried out to characterize 
the origin of this upregulation of ERK1/2 in ENN treated OC. 
A very striking finding of this study has been the effect of ENN in OC. We have 
provided evidence that ENN may actually be a Src kinase inhibitor. Indeed, in the same 
experimental setting, ENN just like PP2 inhibited Src and Akt phosphorylation, 
upregulated the MAPK pathway and downregulated the NFκB pathway. There is no 
doubt that the molecular signaling pathways of ENN and PP2 in OC are similar. 
However, the role of ENN as a Src kinase inhibitor has to be further characterized. In 
particular, in vitro kinase assays have to be performed to confirm these observations and 
thereafter to determine its potency. 
In conclusion, we have shown that the 2 mycotoxins BEA and ENN, although 
structurally related, differentially regulate OC life span. BEA specifically inhibits 
bone resorption and induces apoptosis in pre-fusion OC by a mechanism probably 
involving upregulation of ERK1/2 while ENN specifically inhibits OC survival in a 
Src/Akt dependent manner. These 2 cyclodepsipeptides could therefore be 
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potential candidates for osteoporotic therapies where they could be used alone or 
in combination. 
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Fig. 1. Dose-dependent inhibition of bone resorption with BEA or ENN in mouse-OC. Bone 
marrow cells from femora and tibiae of 6- to 8-weeks-old mice were cocultured for 5 days with 
primary OB from newborn mice on bone slices in 48-well plates. Cells were treated 
immediately with the vehicle (No Treatment) or BEA or ENN in increasing concentrations. 
After culture, bone slices were stained with 1 % toluidine blue for pit area measurement. Data 
are expressed as the mean ± SEM of at least 8 bone slices, *P<0.05; **P<0.01; ***P<0.001 
compared with the No Treatment group. 
 
 
Fig. 2. Dose-dependent inhibition of bone resorption with BEA or ENN in rabbit-OC. OC were 
isolated from long bones of 5 days-old New Zealand white rabbits and cultured in 48-well 
plates, on bone slices for 24 hours, in the presence of the vehicle (No Treatment) or BEA or 
ENN in increasing concentrations. After culture, bone slices were stained with 1 % toluidine 
blue for pit area measurement. Data are expressed as the mean ± SEM of at least 8 bone slices, 
*P<0.05; **P<0.01; ***P<0.001 compared with the No Treatment group. 
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Fig. 3. Dose-dependent and time-dependent inhibition of bone resorption with BEA or ENN in 
mouse-OC. Bone marrow cells from femora and tibiae of 6- to 8-weeks-old mice were 
cocultured with primary OB from newborn mice on bone slices in 48-well plates for 5 days. 
Cells were treated with the vehicle (No Treatment) or BEA (A) or ENN (B)in increasing 
concentrations from day 0, day 2 and/or day 4. After culture, bone slices were stained with 1 % 
toluidine blue for pit area measurement. Data are expressed as the mean ± SEM of at least 8 
bone slices, *P<0.05; **P<0.01; ***P<0.001 compared with the No Treatment group. 
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Fig. 4. BEA and ENN dose-dependently inhibit OC differentiation from bone marrow 
precursors, but not from pre-fusion OC. Bone marrow cells from femora and tibiae of 6- to 8-
weeks-old mice were cocultured with primary OB from newborn mice on coverslips in 6-well 
plates for 5 days. Cells were treated immediately (A) or at day 4 (B) with the vehicle (No 
Treatment) or BEA or ENN in increasing concentrations. After culture, cells were fixed with 3.7 
% formaldehyde in PBS followed by TRAP staining. TRAP-positive multinucleated cells with 3 
or more nuclei were counted. Data are expressed as the mean ± SEM of at least 3 coverslips, 
*P<0.05; **P<0.01; ***P<0.001 compared with the No Treatment group. 
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Fig. 5A and B. Effect of BEA and ENN on the cytoskeleton and apoptosis of OC. (A) Pre-
fusion OC were treated with the vehicle (No treatment) or with BEA or ENN in increasing 
concentrations for 24 hours. Following treatment, cells were fixed with 3.7 % formaldehyde in 
PBS and stained with phalloidin/DAPI. The cytoskeleton was examined on the basis of cell 
shape and F-actin organization. (B) Quantitative representation of OC bearing an actin ring. 
*P<0.05 compared with the No treatment group, scale bars represent 10 µm. 
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Fig. 5C. Effect of BEA and ENN on the cytoskeleton and apoptosis of OC. (C) Apoptotic cells 
were identified based on the fragmentation of nuclei and condensation of chromatin and shown 
here is the quantitative representation. Data are expressed as the mean ± SEM of 3 coverslips, 
*P<0.05 compared with the No treatment group. 
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Fig. 6. Cell viability experiments. (A) OC obtained from coculture were treated with the vehicle 
(No treatment) or BEA or ENN in increasing concentrations for 2, 6 and 12 hours. After 
treatment, cells were fixed with 3.7 % formaldehyde in PBS and TRAP stained. TRAP-positive 
multinucleated cells with 3 or more nuclei were counted. (B) OB or RAW 264.7 cells were 
treated with the vehicle or BEA or ENN in increasing concentrations for 6, 12 and 24 hours. 
Following treatment, the MTS test was performed to determine the number of viable cells. Data 
are expressed as the mean ± SEM of at least 3 wells, *P<0.05; **P<0.01; ***P<0.001 compared 
with the No Treatment group. 
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Fig. 7. Effects of BEA and ENN on OC precursors. OB or RAW 264.7 cells were treated with 
the vehicle or BEA or ENN in increasing concentrations for 6, 12 and 24 hours. Following 
treatment, the DAPI staining was performed and apoptotic cells were identified based on the 
fragmentation of nuclei and condensation of chromatin. Shown here is the quantitative 
representation. Data are expressed as the mean ± SEM of at least 3 wells, *P<0.05; **P<0.01; 
***P<0.001 compared with the No Treatment group. 
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Fig. 8A. Signal transduction of BEA in RAW 264.7-derived OC. RAW 264.7 were stimulated 
with rmRANKL at 50 ng/ml to allow differentiation in OC. After culture, cells were treated 
with BEA 1 µM for 1, 15, 60 and 120 min. Cells were then lysed, elctrophoresed and the 
western blot was carried out to determine the level of indicated proteins. All experiments were 
carried out at least in triplicate and representative radiographs are shown. 
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Fig. 8B. Signal transduction of ENN in RAW 264.7 derived OC. RAW 264.7 were stimulated 
with rmRANKL at 50 ng/ml to allow differentiation in OC. After culture, cells were treated 
with ENN 10 µM for 1, 15, 60 and 120 min. Cells were then lysed, elctrophoresed and the 
western blot was carried out to determine the level of indicated proteins. All experiments were 
carried out at least in triplicate and representative radiographs are shown. 
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Fig. 9A and B. Signal transduction of BEA and ENN in coculture-derived OC. Mouse bone 
marrow cells were cocultured with primary OB from newborn mice for 5 days in presence of 1 
nM vitamin D3 and 1 µM PGE2 to generate OC. Afterwards, OC were starved in medium 
containing 0.5 % FCS for 15 min, then treated with BEA 1 µM (A) or ENN 10 µM (B) for 1, 
15, 60 and 120 min. Following treatment, cells were lysed, elctrophoresed and the western blot 
was performed to determine the level of indicated proteins. All experiments were carried out at 
least in triplicate and representative radiographs are shown. 
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Fig. 9C. Signal transduction of PP2 in coculture-derived OC. (C) Mouse bone marrow cells 
were cocultured with primary OB from newborn mice for 5 days in presence of 1 nM vitamin 
D3 and 1 µM PGE2 to generate OC. Afterwards, OC were starved in medium containing 0.5 % 
FCS for 15 min, then treated with PP2 10 µM for 1, 15, 60 and 120 min. Following treatment, 
cells were lysed, elctrophoresed and the western blot was performed to determine the level of 
indicated proteins. All experiments were carried out at least in triplicate and representative 
radiographs are shown. 
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Fig. 9D. Signal transduction of BEA and PP2 in coculture derived OC. Mouse bone marrow 
cells were cocultured with primary OB from newborn mice for 5 days in presence of 1 nM 
vitamin D3 and 1 µM PGE2 to generate OC. Afterwards, OC were starved in medium 
containing 0.5 % FCS for 15 min, pretreated with PP2 (10 µM) 1 hour before addition of BEA 1 
µM for 15 or 60 min. Following treatment, cells were lysed, elctrophoresed and the western blot 
was performed to determine the level of indicated proteins. All experiments were carried out at 
least in triplicate and representative radiographs are shown. 
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Fig. 9E. Signal transduction of ENN and PD98059 in coculture derived-OC. Mouse bone 
marrow cells were cocultured with primary OB from newborn mice for 5 days in presence of 1 
nM vitamin D3 and 1 µM PGE2 to generate OC. Afterwards, OC were starved in medium 
containing 0.5 % FCS for 15 min, pretreated with PD98059 (50 µM) 1 hour before addition of 
ENN 10 µM for 1 or 15 min. Following treatment, cells were lysed, elctrophoresed and the 
western blot was performed to determine the level of indicated proteins. All experiments were 
carried out at least in triplicate and representative radiographs are shown. 
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Abstract 
 
The skeleton is one of the most preferred locations in the body to which cancer, 
particularly from breast, lung and prostate metastasizes. Bone metastases therefore 
constitute a common cause of morbidity and mortality in cancer patients and to date, the 
treatment is primary palliative. We investigated the effects of 2 well-described 
cyclodepsipeptides beauvericin (BEA) and enniatins (ENN) on 2 highly tumorigenic, 
hormone-independent cell lines MDA-MB-231 and PC3, and on a non metastatic cell 
line U2OS with characteristics of primary tumor of bone. The drug concentrations used 
ranged from 0.1 to 10 µM and the incubation times from 2 to 48 h. Herein, we report 
inhibition of cell growth, cell viability and induction of apoptosis in the above 
mentioned cancer cell lines. At lower concentrations (0.1 and 1 µM), ENN time-
dependently (24 to 48 h) and significantly (up to 50 % inhibition after 48 h treatment of 
PC3 with 1 µM ENN, p<0.001 vs. control) inhibited proliferation of metastatic cells 
(MDA-MB-231 and PC3) compared to BEA. However, BEA exerted more cell growth 
inhibitory effect at higher concentration (10 µM) in all 3 cell lines as compared to ENN. 
BEA and ENN similarly affected the metastatic and non metastatic cell viability, as 
early as 24 h, with a significant effect observed already with 5 µM drug (p<0.001 vs. 
control). Both inhibitors more potently induced apoptosis after 24 h in metastatic cells 
when compared to non metastatic, with ENN being more apoptotic than BEA. This 
apoptotic effect was significant with 5 µM BEA in MDA-MB-231 (p<0.01), 10 µM 
BEA in PC3 (p<0.001), 5 µM ENN in MDA-MB-231 (p<0.001), 5 µM ENN in PC3 
(p<0.01) and 10 µM ENN in U2OS (p<0.01). Interestingly, the metastatic profile of the 
cells did not seem to confer any selective advantage for the effects of both inhibitors at 
the molecular level. Indeed, while the p38 MAPK pathway remained continuously 
activated (from 6 to 24 h) in all cell lines, BEA and ENN inactivated ERK in MDA-
MB-231 as opposed to its upregulation in PC3 and U2OS. Moreover, BEA was able to 
induce PARP cleavage in all cell lines, whereas ENN did so only in PC3 cells. Finally, 
the cell-cell adhesion molecule E-cadherin, whose loss of expression and/or activity has 
been implicated in the progression of metastasis, was upregulated in all cell lines 
following BEA or ENN treatment. These data support the antitumoral effects of 
cyclodepsipeptides and their therapeutic value in the treatment of bone cancer and 
skeletal metastases. 
 
Key words: apoptosis, cyclodepsipeptides, metastasis, MAPK pathway 
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1. Introduction 
 
Metastatic cancer cells have the ability to break away from their primary site, enter 
lymphatic and blood vessels, circulate through the bloodstream, and invade other parts 
of the body (secondary organs) where they settle anew. Theoretically, any secondary 
organ is susceptible to metastasis; however, the three main organs usually affected are 
the lungs, liver and bone. Actually, the skeleton is the place of choice for metastasis to 
develop. Over 60 % of patients with nonosseous primary malignant neoplasms present 
abnormal bone scans [1] and particularly, breast, lung and prostate cancer constitute the 
major source of all metastases to bone [2,3]. It is well known that the Batson venous 
plexus, a network of valveless veins in the human body, directly connects primary 
tumor sites (breast or prostate) with the skeleton bypassing the liver and lungs [4]. 
Additionally, tumour cells are known to form emboli that can be easily trapped in 
capillary beds within the bone [5]. More importantly, once the tumor cells reach the 
skeleton, growth factors released in the bone microenvironment during the process of 
bone remodeling together with those released by the tumour cells provide a “fertile soil” 
that favors interaction of cancer cells with bone cells, stimulation of tumour cell growth 
and bone remodeling, and development of metastases [5,2]. 
BEA and ENN are structurally related cyclodepsipeptides mycotoxins produced by 
Fusarium, Beauveria, Paecilomyces and Polypovirus [6-13]. They exhibit antibiotic 
[14,15], hydrophobic [16], ionophoric [17-19], insecticidal [20,21,9], phytopathogenic 
and non mutagenic properties [22,15], and are cytotoxic to several mammalian and 
cancer cell line models [23-27]. Recently (unpublished), we demonstrated that these 2 
mycotoxins inhibit bone resorption. BEA induced apoptosis in osteoclasts by 
mechanisms likely involving ERK1/2 phosphorylation while ENN affected their 
survival by downregulating the Src/Akt pathway. As bone resorption is likely to be the 
main mechanism in the early stages of bone metastasis, and probably the main 
mechanism by which osteolysis in breast and prostate cancer patient progresses 
[5,28,3], it is anticipated that the two cyclodepsipeptides might actually reduce or 
eventually inhibit metastasis in the bone microenvironment. However, whether or not 
they can directly inhibit tumour cell growth itself, in particular the breast or prostate 
cancer cells that are known to highly metastasize to the skeleton remains unclear. In 
previous reports, serratamolide (AT514), a cyclodepsipeptide isolated from Serratia 
marcescens induced cell cycle arrest and apoptosis in B-cell chronic lymphocytic 
leukemia [29] and breast cancer cells [30]. Therefore, we investigated the effects of the 
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two cyclodepsipeptides BEA and ENN on breast (MDA-MB-231), prostate (PC3) and 
osteosarcoma (U2OS) cell lines. Herein, we show that BEA and ENN inhibit cell 
growth, cell viability and induce apoptosis in these cell lines irrespective of their 
metastatic profile by mechanisms likely involving the MAPK signaling. 
 
2. Materials and methods 
 
2.1. Drugs 
 
The substances used were 2 mycotoxins BEA (#B-7510) and ENN (#E-3643) both 
produced as a desiccate by Sigma-Aldrich Chemie (Taufkirchen, Germany). ENN had a 
purity of approximately 96 %, a molecular weight of 681.5 g/mol and was composed of 
3 % enniatin A, 20 % enniatin A1, 19 % enniatin B and 54 % enniatin B1. BEA was of 
99 % purity with a molecular weight of 784 g/mol. The concentrations used ranged 
from 0.1 µM to 10 µM. The substances were dissolved in absolute ethanol to make 
stock solutions at 1 mM, 5 mM and 10 mM. 
 
2.2. Cell culture 
 
The metastatic breast cancer MDA-MB-231, the metastatic prostate cancer PC3 and the 
osteosarcoma cell line U2OS were obtained from the American Type Culture Collection 
(ATCC). They were grown in α-modification of the minimal essential medium (α-
MEM) supplemented with 10 % heat inactivated FCS (Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany), 100 U/ml of penicillin (Life Technologies Inc. Grand Island, 
USA) and 100 µg/ml streptomycin (Life Technologies Inc. Grand Island, USA). Cell 
culture was performed at 37 °C in a humidified 5 % CO2 atmosphere. 
 
2.3. Growth inhibition assay 
 
MDA-MB-231 (15x104 cells/well), PC3 (23x104 cells/well) and U2OS (7x104 
cells/well) were seeded in triplicates in 6-well plates (Greiner Bio-One GmbH, 
Frickenhausen, Germany) and allowed to attach for 2 days. Cells were then treated with 
the vehicle (absolute ethanol, final concentration in cultures 1 ‰ v/v) or drug (BEA or 
ENN) in increasing concentrations for 24 and 48 hours. Before treatment, cells of 3 
wells (each well handled separately) were enzymatically detached, collected and 
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counted using the Casy cell counter (Model DT, Schärfe system, Germany). The 
average count at this step was considered as the starting time 0 cell density for all 
vehicle and treated groups. At different time points, cells were enzymatically detached, 
collected, counted and the average cell density per treated group (n=3 wells/group) was 
compared to the average cell density of the vehicle group at that specific time point. The 
experiment was repeated 3 times and data are presented as mean ± SEM. 
 
2.4. Cell Viability assay 
 
The MTS-test was used to determine the number of viable cells in culture. This method 
involves the CellTiter 96®AQueous One Solution Reagent (#G3580, Promega, Madison, 
WI, USA,) composed of 1.90 mg/ml MTS and 300 µM PES in Dulbecco’s buffered 
saline, pH 6.0. MDA-MB-231 (37x103 cells/well), PC3 (37x103 cells/well) and U2OS 
(25x103) were seeded in 96-well plate (Iwaki, Asahi Techno Glass, Japan), 8 wells per 
groups, and allowed to attach for 24 hours. Thereafter, cells were submitted to the 
vehicle or drug in increasing concentrations for another 24 and 48 hours. Before 
termination, the cells were incubated with 20 µl of the CellTiter reagent for 2 hours and 
the absorbance was read at 490 nm with a Multiskan plate reader (Labsystems Mult 
45139, Finland). The data were collected using Delta Soft3 software and the results are 
presented as a proportion of viable cells in the presence of BEA or ENN compared to 
the vehicle group. 
 
2.5. Apoptosis assay 
 
The DAPI staining was performed to assess apoptosis. MDA-MB-231 (16x104 
cells/well), PC3 (8x104 cells/well) and U2OS (8x104 cells/well) were seeded on 
coverslips (Menzel-Glaser, Germany) in triplicate in 6-well plates and allowed to attach 
for 24 hours. Cells were then treated with the vehicle or drug in increasing 
concentrations for another 24 hours. After culture, cells were fixed for 13 min with 3.7 
% formaldehyde (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) in PBS at room 
temperature. Thereafter, cells were incubated with 0.1 µg/ml of the DAPI reagent (4’,6-
Diamidino-2-phenylindole, Sigma-Aldrich) in PBS for 15 min at 37 °C, 5 % CO2. The 
coverslips were mounted onto microscopes glass slides (Menzel-Glaser, Germany) 
using fluorosave embedding medium (bioMérieux® sa, Mary l’Etoile-France), sealed 
with Fixogum rubber cement (Marabuwerke GmbH & Co.KG, Germany) and stored at 
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4 °C in the dark. Stained coverslips were examined under a fluorescence microscope 
(Nikon, Japan) using the DAPI filter and a 60x objective with immersion oil. Data were 
collected using Cell*F software (Cell Imaging System). Apoptotic cells were identified 
based on the shrinking and fragmentation of nuclei, as well as condensation of 
chromatin. 
 
2.6. Western blotting experiments 
 
MDA-MB-231 (33x104 cells/well), PC3 (16x104 cells/well) and U2OS (16x104 
cells/well) were cultured in 6-well plates until confluency (2 to 3 days). Cells were then 
submitted to the vehicle or 5 µM of drug in starvation medium (containing only 0.5 % 
heat inactivated FCS) for 2, 6, 12 and 24 hours. After treatment, cells were washed 
several times with ice-cold PBS and lysed in lysis buffer (50 mM NaCl, 10 mM Tris-
base, 1 % Triton X-100, pH 7.05) containing several inhibitors of proteases and 
phosphatases (50 mM NaF, 10 µg/ml Aprotinin, 10 µg/ml Leupeptin, 1 µg/ml Pepstatin, 
2 mM Orthovanadate, 1mM PMSF). The Bio-Rad DC protein assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA) was used to quantify the proteins in the samples. 
About 30 µg of proteins per sample were resolved on 10 % SDS-PAGE according to 
their molecular weight, electrotransferred onto a 0.45 µm nitrocellulose membrane 
(Whatman GmbH, Dassel, Germany), blocked for one hour in 5 % non fat dry milk in 
Tris Buffer Saline Tween (TBST 0.1%) and incubated overnight with the primary 
antibody in TBST 0.1 %. Afterwards, the proteins were incubated for one hour with the 
secondary antibody (HRP-conjugated anti-mouse or anti-rabbit) (1:5000 in TBST) and 
the detection was performed with an enhanced chemoluminescence detection kit (GE 
Healthcare, UK). The membranes were stripped and reprobed several times and ß-actin 
served as control for equal loading. 
The primary antibodies used were anti phospho Src-Tyr416 (1:1000, rabbit polyclonal, 
#2101, 60 kDa), anti phospho Akt-Ser 473 (1:1000, rabbit monoclonal, #4060, 60 kDa), 
anti phospho NF-κB p65-Ser536 (1:1000, rabbit monoclonal, #3033, 65 kDa), anti 
phospho-p38 MAPK Thr180/Tyr182 (1:1000, rabbit polyclonal, #9211, 43 kDa), anti 
caspase 3 (1:1000, rabbit polyclonal, #9662, 35 kDa) and anti cleaved PARP (1:1000, 
rabbit polyclonal, #9544, 89 kDa) from Cell Signaling, Inc (Beverly, MA, USA). Anti 
phospho p-44/42 MAPK Thr202/Tyr204 (1:1000, mouse monoclonal, #9106, 44/42 
kDa) was from New England Biolabs, Inc (Ipswich, MA, USA). Anti E-cadherin 
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(1:2500, mouse monoclonal, #C20820, 120 kDa), anti FAK (1:1000, mouse 
monoclonal, #F15020, 125 kDa) and anti STAT3 (1:2500, mouse monoclonal, 
#S21320, 92 kDa) were purchased from Transduction Laboratories (Lexington, KY, 
USA). Anti PI3 kinase α (333) (1:1000, rabbit polyclonal, #sc-423, 85 kDa) was from 
Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA) and anti ß-actin (1:2000, mouse 
monoclonal, #A-2228, 42 kDa) from Sigma (St. Louis, MO, USA). The secondary 
antibodies anti-mouse IgG HRP-conjugate (# W4021) and anti-rabbit IgG HRP-
conjugate (#W4011) were from Promega (Madison, WI, USA). 
 
2.7. Statistical analyses 
 
All experiments were repeated at least 3 times. Data were analysed using one factor 
ANOVA (analysis of variance) incorporated in the StatView statistical program and are 
presented as mean ± SEM. Significant differences between groups are presented as * 
p<0.05; ** p<0.01; *** p<0.001 in the treatment group compared to the vehicle. 
 
3. Results 
 
3.1. BEA and ENN inhibit cell growth of MDA-MB-231, PC3 and U2OS 
 
At first, we investigated the effects of cyclodepsipeptides BEA and ENN on the 
proliferation of MDA-MB-231, PC3 and U2OS cancer cell lines. We allowed these 
cells to grow in presence of drug in increasing concentrations (0.1 to 10 µM) for 24 and 
48 h (Fig.1). 
At higher concentration (10 µM), BEA and ENN significantly and time-dependently 
inhibited MDA-MB-231 cell growth (P<0.001), with however more effect of BEA than 
ENN (Fig. 1a). At lower concentrations (0.1 and 1 µM), BEA did not affect cell growth, 
whereas ENN dose and time-dependently inhibited cell proliferation. Indeed, the 
inhibition was observed already at 0.1 µM for 48 h (p<0.01), and increased with 
concentration and time (p<0.001 at 24 and 48 h for 1 and 10 µM). Therefore, ENN was 
more potent (at lower concentrations) at inhibiting MDA-MB-231 cell growth as 
compared to BEA. 
At 10 µM, BEA and ENN similarly inhibited PC3 cell growth (Fig. 1b), in a significant 
and time-dependent pattern (P<0.001). Although both compounds exerted significant 
inhibition at lower concentration (BEA 1 µM, ENN 0.1 and 1 µM), ENN was proven to 
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be more potent than BEA, as 50 % inhibition was observed within 48 h (ENN 1 µM) 
incubation. Moreover, the inhibition was observed already at 0.1 µM (24 h, p<0.05) and 
increased with concentration and time (p<0.001 at 24 and 48 h for 1 and 10 µM). 
BEA significantly inhibited U2OS cell growth at 1 µM (48 h, p<0.01) and 10 µM 
(p<0.001 at both time points) (Fig. 1c). ENN inhibited cell growth only at 10 µM 
(p<0.01 at 24 h, p<0.001 at 48 h). Therefore, in this specific cell line, BEA was more 
potent at inhibiting growth as compared to ENN. 
 
3.2. BEA and ENN affect cell viability of MDA-MB-231, PC3 and U2OS 
 
Viability is an unquestionable requirement for a cell to fulfill in order to proliferate. We 
next investigated the effect of both compounds on viability of MDA-MB-231, PC3 and 
U2OS by MTS test as described in the materials and methods section. 
BEA and ENN similarly affected MDA-MB-231 viability after 24 h incubation, with a 
significant effect at 5 and 10 µM (p<0.001) (Fig. 2a). This effect was pronounced after 
48 h, where an additional inhibition was observed at 1 µM (p<0.001). However, ENN 
was more potent as compared to BEA given that the viability was affected even at the 
lowest ENN concentration (0.1 µM, 48 h, p<0.001). 
BEA and ENN similarly inhibited PC3 viability after 24 h incubation, with a significant 
effect at 5 and 10 µM (p<0.001) (Fig. 2b). This inhibition increased with time, with an 
additional effect at 1 µM (p<0.05) after 48 h. 
BEA and ENN similarly and significantly affected U2OS viability at 5 and 10 µM after 
24 and 48 h treatment (p<0.001) (Fig. 2c). 
 
3.3. BEA and ENN induce apoptosis in MDA-MB-231, PC3 and U2OS 
 
Apoptosis is a process of programmed cell death in multicellular organisms. We 
evaluated apoptosis induced after 24 h of BEA or ENN treatment in MDA-MB-231, 
PC3 and U2OS by DAPI staining. Features characteristic of apoptosis include 
shrinking, condensation of chromatin and fragmentation of nuclei (Fig. 3a). 
BEA induced apoptosis in MDA-MB-231 cells with a significant effect at 5 µM 
(p<0.01) (Fig. 3b). ENN also induced apoptosis in these cells at 1 µM (p<0.05), 5 µM 
(p<0.001) and 10 µM (p<0.05). However, ENN was more apoptotic as compared to 
BEA although 5 µM remained the most apoptotic concentration for both compounds. 
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BEA and ENN dose-dependently induced apoptosis in PC3 cells (Fig. 3c). The effect of 
ENN was significant as early at 1 µM (p<0.05) and increased at 5 and 10 µM (p<0.01) 
whereas BEA’s effect was significant only at 10 µM (p<0.001). 
BEA induced apoptosis in U2OS although the effect was not significant (Fig. 3d). 
However, ENN more potently and dose-dependently induced apoptosis in these cells 
with a significant effect observed at 10 µM (p<0.01). 
 
3.4. Molecular signaling experiments 
 
We have demonstrated that BEA and ENN inhibit cell growth, cell viability and induce 
apoptosis in metastatic (MDA-MB-231 and PC3) and non metastatic (U2OS) cell lines. 
Next, we sought to determine the molecular events underlying such biological 
responses. Deregulation of kinase activities has emerged as a major mechanism by 
which cancer cells evade normal physiological constraints on growth and survival. 
Therefore, we screened the kinase activities altered following treatment with both 
inhibitors. 
MDA-MB-231, PC3 and U2OS were first cultured in 6-well plates until confluency, 
and then treated with the vehicle or 5 µM of drug in starvation medium for 2 to 24 h. 
The drug concentration chosen was 5 µM, as this was the concentration where 
significant inhibition was observed with regard to cell viability and/or apoptosis. 
 
3.4.1. MDA-MB-231 
 
The c-Src non-receptor tyrosine kinase is overexpressed and activated in a large number 
of human malignancies, and has been associated to the development of cancer and 
progression to distant metastases. Herein, we report a downregulation of c-Src, Akt, 
ERK and NFκB after 12 h with BEA and after 24 h with BEA or ENN (Fig. 4a). PI3 
kinase was downregulated after 12 h only with BEA, whereas p38 showed sustained 
activation from 6 to 24 h following exposure of cells to each of the 2 compounds. We 
next examined whether the intrinsic mitochondrial pathway leading to apoptosis was 
affected. The effector caspase 3 was not affected while PARP was cleaved after 2, 6 and 
24 h following BEA treatment. Stat3 and E-cadherin have been associated with the 
development of metastases. BEA downregulated Stat3 after 12 and 24 h, while BEA 
and ENN showed sustained upregulation of E-cadherin from 2 to 24 h. FAK promotes 
cell adhesion, cell migration and thereby metastatic potential of cancer cells. Herein, 
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FAK was downregulated after 2 h (with ENN), 6 h (with BEA) and 24 h (with BEA or 
ENN). 
 
3.4.2. PC3 
 
c-Src, PI3 kinase and NFκB were downregulated after 24 h, unlike Akt that was 
activated after 12 and 24 h following BEA or ENN treatment (Fig. 4b). Upon treatment, 
the 2 components of the MAPK pathway showed early (p38 after 6 h and ERK after 12 
h) and sustained activation over time. Caspase 3 was not affected, whereas PARP 
cleavage was observed after 2 to 24 h treatment with BEA or ENN. Stat3 showed slight 
activation following ENN treatment (2 and 12 h), E-cadherin was upregulated by BEA 
(2, 12 and 24 h) or ENN (2 and 12 h), and FAK was downregulated after 24 h treatment 
with ENN. 
 
3.4.3. U2OS 
 
c-Src was not affected by BEA and interestingly, was even activated following 24 h 
ENN treatment (Fig. 4c). PI3 kinase was downregulated (after 24 h), whereas Akt 
showed sustained activation from 2 to 24 h treatment with each of the 2 compounds. 
BEA or ENN induced upregulation of the MAPK pathway. NFκB was inactivated after 
24 h exposure of cells to BEA or ENN whereas ENN, but not BEA slightly activated 
caspase 3 (24 h). Unlike BEA (6 to 12 h), ENN did not induce PARP cleavage. 
Moreover, BEA or ENN did not affect Stat3. BEA (2 and 12 h) or ENN (2 and 6 h) 
promoted a transient E-cadherin expression followed by return to basal levels. FAK was 
first activated by BEA (12 h) or ENN (2 h), and finally downregulated after 24 h. 
 
4. Discussion 
 
Bone metastases are a frequent cause of morbidity in cancer patients. They are 
associated with bone pain, pathological fractures, hypercalcaemia and spinal cord or 
nerve root compression, all of which may profoundly impair a patient’s quality of life 
[31]. To date, treatment of bone metastases is primarily palliative, and despite 
remarkable advances in the field, there is an important need to target bone metastases by 
developing drugs that preferentially target cancer cells in bone in addition to bone 
stroma, given that skeletal metastases are more refractory to treatment, constitute the 
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highest load of tumour mass in the body, function as secondary site for tumour spread, 
and are associated with significant morbidity [5]. 
We have investigated the effects of 2 well-known mycotoxins (BEA and ENN), on 2 
highly tumorigenic hormone-independent cell lines MDA-MB-231 and PC3, and on a 
primary tumor of bone cell line model U2OS. Herein, we report inhibition of cell 
growth, cell viability and induction of apoptosis in the above mentioned cancer cell 
lines. 1) ENN significantly inhibited cell growth and induced apoptosis in metastatic 
cells (MDA-MB-231 and PC3) as compared to BEA. 2) However, BEA was more 
potent at inhibiting the non metastatic U2OS cell growth as compared to ENN. 3) The 2 
inhibitors affected cell viability and induced apoptosis more potently in metastatic cells 
as compared to the non metastatic one. These data suggest a cell type and tumorigenic 
specific effect of drug. 
Several anti-cancer agents, including genistein [32,33], indole-3-carbinol [34], 
resveratrol [35], grifolin [36], protoapigenone [37] and ß-inone [38] exhibit inhibitory 
and proapoptotic effects, and this is consistent with our findings. Moreover, the 
compounds used here, namely BEA and ENN, have previously shown cytotoxic effects 
in other cancer cell models [23-25,39]. Serratamolide (AT514), a structurally related 
cyclodepsipeptide isolated from Serratia marcescens has been reported to induce cell 
cycle arrest and apoptosis in B-cell chronic lymphocytic leukemia [29] and breast 
cancer cells [30]. Our findings are in line with these previous works and support the 
anti-cancer effect of cyclodepsipeptides, as well as their therapeutic potential in the 
treatment of bone metastases. 
The pathophysiology of cancer involves deregulation of a number of molecules at the 
molecular level that play critical roles in cell growth, migration, invasion and 
metastases. Considerable evidence implicates elevated expression and/or activity of Src 
in cancer development [40]. Src inhibition reduced growth, adhesion, motility and 
invasion of prostate cancer cells in vitro [41], and reduced incidence of breast cancer 
metastases in vivo [42]. More importantly, reduction of c-Src activity induced osteoclast 
apoptosis in vivo and in vitro [43], and since bone resorption is likely to be the main 
mechanism in the early stages of bone metastasis and probably the main mechanism by 
which osteolysis in breast and prostate cancer patient progresses [5,28,3], Src inhibition 
represents a valuable therapeutic target [44-46] and should be validated by any potential 
anti-cancer agent aimed at treating bone metastases. Accordingly, we observed an 
inhibition of c-Src following treatment of metastatic cell lines with BEA or ENN. 
However, BEA did not affect Src activity, whereas ENN even stimulated it in the non 
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metastatic U2OS cell line, suggesting that Src is not involved in the inhibitory effects of 
BEA and ENN in these particular cells. The signal transducer and activator of 
transcription 3 (Stat3) promotes metastatic progression of prostate cancer [47], and is a 
downstream target of Src-mediated inhibitory effects of the phytoalexin resveratrol in 
malignant cells [35]. In our context, BEA but not ENN inactivated Stat3 in MDA-MB-
231 cells. However, Stat3 was not affected in U2OS, as opposed to its activation in PC3 
following ENN treatment. Whether or not Stat3 mediates Src-dependent inhibition of 
MDA-MB-231 cells following BEA treatment is still unclear, although both proteins 
were downregulated. Additionally, our data suggest that Stat3 is not downstream of Src 
in BEA or ENN inhibitory effects in PC3 and U2OS. 
The PI3 kinase/Akt pathway is known to promote cell survival by inhibiting apoptosis 
[36,48]. PI3 kinase was slightly inactivated in breast cells by BEA (12 h), and 
downregulated in prostate and osteosarcoma cells following BEA or ENN treatment (24 
h). However, although Akt was inhibited as well in breast cells, it appeared to be 
continuously activated in prostate and osteosarcoma cells. So while the PI3 kinase/Akt 
pathway may contribute to the apoptotic effects of BEA and ENN in MDA-MB-231 
cells, the involvement of this pathway in BEA or ENN induced apoptosis in PC3 and 
U2OS deserves further investigation. 
The mitogen-activated protein kinase (MAPK) family of proteins regulates extracellular 
signals that lead to proliferation, differentiation and survival. The extracellular signal 
regulated kinase (ERK)/MAPK pathway primarily directs a program of proliferation 
and survival [49], while the p38 MAPK is activated upon cellular stress and engages 
pathways that can block proliferation or promote apoptosis [50-55]. There is increasing 
evidence that p38 MAPK negatively regulates tumorigenesis [56,57], and selectively 
mediates oxidative stress (reactive oxygen species)-induced cancer cell apoptosis [58]. 
In this study, BEA and ENN induced ERK activation in PC3 and U2OS, unlike in 
MDA-MB-231 where a downregulation was observed. Interestingly, p38 MAPK was 
continuously activated in all cell lines. Downregulation of ERK has been associated to 
growth inhibition in other cell types [59-61] and may contribute, at least in part, to the 
inhibitory effects of BEA and ENN in MDA-MB-231 cells, but not in PC3 and U2OS 
cells, whose proliferation was inhibited as well. However, ERK activation has been 
reported to mediate apoptosis following DNA damage in other studies [62-64], and this 
is consistent with our observations in PC3 and U2OS. Moreover, our findings that BEA 
and ENN inhibit proliferation, induce apoptosis in MDA-MB-231, PC3 and U2OS, and 
activate the p38 MAPK pathway are in line with previous reports [60,65]. Keeping in 
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mind that p38 MAPK selectively mediates reactive oxygen species (ROS)-induced 
apoptosis, it is still a matter of debate whether or not mycotoxins do actually produce 
ROS. Indeed, Dornetshuber et al. recently demonstrated that the mycotoxins BEA and 
ENN exert moderate antioxydative activities, and that generation of ROS is not 
involved in their apoptotic effects [66]. However, BEA was found to induce a 4 fold 
increase of ROS [67] that correlated with reduced cell viability, lipid peroxidation and 
glutathione depletion [67,68]. Taken together, these data suggest the involvement of the 
MAPK signaling in the BEA and ENN inhibitory and/or apoptotic effects in metastatic 
and non metastatic cell lines. 
Chemotherapeutic agents are known to induce nuclear factor kappa B (NFκB) activity 
in tumour cells, resulting in lower cell death and drug resistance. The NFκB pathway is 
activated upon binding of the receptor activator of NFκB ligand (RANKL) to its 
receptor RANK expressed on cancer cells, and regulates cell migration and bone 
metastasis [69]. Moreover, inhibition of the Akt/NFκB survival pathway is important 
for apoptosis induced by indole-3-carbinol (common phytochemical in cruciferous 
vegetables) [70], serratamolide (cyclodepsipeptide) [29], 3,3’-diindolylmethane (major 
in vivo acid-catalyzed condensation product of indole-3-carbinol) [71] and genistein 
(soybean isoflavone) [72]. Herein, BEA and ENN inactivate the NFκB pathway in 
MDA-MB-231, PC3 and U2OS. However, Akt was downregulated only in MDA-MB-
231 cells, and we have not provided evidence of any relation between Akt and NFκB in 
our setting. Yet, BEA or ENN-induced NFκB inactivation in our cancer cells is an 
undeniable benefit for these compounds and deserves further investigation. 
DNA damage, ischemia and oxidative stress are apoptotic signals that lead to cell death 
through the intrinsic mitochondrial pathway, involving release of cytochrome c, 
activation of caspases, and cleavage of poly-ADP-ribose polymerase (PARP). BEA, but 
not ENN, induced PARP cleavage in MDA-MB-231 and U2OS cells. However, BEA 
and ENN did not affect caspase 3 activation, although they induced PARP cleavage in 
PC3 cells. These data suggest cell type specific effects of our compounds in 
mitochondrial-induced apoptosis, and so far, the mitochondrial pathway has been 
implicated in cyclodepsipeptides [24,29,25,26,39,30], as well as other anti-cancer 
agents [73,36,74,38]-induced apoptosis. 
Loss of the cell-cell adhesion molecule E-cadherin expression or function is implicated 
in tumor invasion, progression and metastasis, and is associated with poor prognosis in 
breast and prostate cancer patients [75,76]. Interestingly, E-cadherin appeared to be 
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upregulated by BEA and ENN irrespective of the metastatic profile. Aberrant 
expression, activity and signaling of FAK can potentially promote the progression of 
several types of tumors in vivo [77], and alterations of the FAK/Src signal transduction 
pathway correlate with increased migratory capacity of prostate carcinoma cells [78]. In 
this study, BEA and ENN inactivated FAK in MDA-MB-231 and U2OS whereas in 
PC3 cells, only ENN induced FAK inactivation. These data suggest that BEA and ENN 
trigger cell type specific responses to growth and migration, and that these are 
independent of their metastatic profile. 
To summarize, BEA and ENN affected cell viability and induced apoptosis more 
potently in metastatic cells (MDA-MB-231 and PC3) as compared to the non 
metastatic one (U2OS). Interestingly, the metastatic profile of the cells did not 
confer any selective advantage for the effects of our inhibitors at the molecular 
level. While BEA more commonly interfered with the MAPK and the 
mitochondrial apoptotic pathways in all cell lines, ENN interacted predominantly 
with the MAPK signaling. 
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Fig. 1a. Growth inhibition assay: MDA-MB-231 (15x104 cells/well) were seeded in triplicates 
in 6-well plates and allowed to attach for 2 days. The cells were then treated with the vehicle 
(absolute ethanol) or drug (BEA or ENN) in increasing concentrations for 24 and 48 hours. 
After treatment, cells were enzymatically detached, collected, counted and the average cell 
density per treated group (n=3 wells/group) was compared to the average cell density of the 
vehicle group at that specific time point. The experiment was repeated 3 times and data are 
presented as mean ± SEM. 
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Fig. 1b. Growth inhibition assay: PC3 (23x104 cells/well) were seeded in triplicates in 6-well 
plates and allowed to attach for 2 days. The cells were then treated with the vehicle (absolute 
ethanol) or drug (BEA or ENN) in increasing concentrations for 24 and 48 hours. After 
treatment, cells were enzymatically detached, collected, counted and the average cell density per 
treated group (n=3 wells/group) was compared to the average cell density of the vehicle group 
at that specific time point. The experiment was repeated 3 times and data are presented as mean 
± SEM. 
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Fig. 1c. Growth inhibition assay: U2OS (7x104 cells/well) were seeded in triplicates in 6-well 
plates and allowed to attach for 2 days. The cells were then treated with the vehicle (absolute 
ethanol) or drug (BEA or ENN) in increasing concentrations for 24 and 48 hours. After 
treatment, cells were enzymatically detached, collected, counted and the average cell density per 
treated group (n=3 wells/group) was compared to the average cell density of the vehicle group 
at that specific time point. The experiment was repeated 3 times and data are presented as mean 
± SEM. 
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Fig. 2a. Cell viability assay: MDA-MB-231 (37x103 cells/well) were seeded in 96-well plate, 8 
wells per group, and allowed to attach for 24 hours. Thereafter, cells were submitted to the 
vehicle or drug in increasing concentrations for another 24 and 48 hours. Before termination, 
cells were incubated with 20 µl of the CellTiter reagent for 2 hours and the absorbance was read 
at 490 nm with a Multiskan plate reader. The results are presented as the proportion of viable 
cells in the presence of BEA or ENN compared to the vehicle group. * p<0.05; ** p<0.01; *** 
p<0.001 in the treatment group compared to the vehicle. 
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Fig. 2b. Cell viability assay: PC3 (37x103 cells/well) were seeded in 96-well plate, 8 wells per 
group, and allowed to attach for 24 hours. Thereafter, cells were submitted to the vehicle or 
drug in increasing concentrations for another 24 and 48 hours. Before termination, cells were 
incubated with 20 µl of the CellTiter reagent for 2 hours and the absorbance was read at 490 nm 
with a Multiskan plate reader. The results are presented as the proportion of viable cells in the 
presence of BEA or ENN compared to the vehicle group. * p<0.05; ** p<0.01; *** p<0.001 in 
the treatment group compared to the vehicle. 
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Fig. 2c. Cell viability assay: U2OS (25x103) were seeded in 96-well plate, 8 wells per group, 
and allowed to attach for 24 hours. Thereafter, cells were submitted to the vehicle or drug in 
increasing concentrations for another 24 and 48 hours. Before termination, cells were incubated 
with 20 µl of the CellTiter reagent for 2 hours and the absorbance was read at 490 nm with a 
Multiskan plate reader. The results are presented as the proportion of viable cells in the presence 
of BEA or ENN compared to the vehicle group. * p<0.05; ** p<0.01; *** p<0.001 in the 
treatment group compared to the vehicle. 
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Fig. 3a and b. Apoptosis assay: MDA-MB-231 (16x104 cells/well), PC3 (8x104 cells/well) and 
U2OS (8x104 cells/well) were seeded on coverslips in triplicate in 6-well plates and allowed to 
attach for 24 hours. Cells were then treated with the vehicle or drug in increasing concentrations 
for another 24 hours. After treatment, cells were fixed with 3.7 % formaldehyde in PBS and 
nuclei were stained with DAPI. (A) is the qualitative representation of MDA-MB-231, PC3 and 
U2OS. (B) is the quantitative representation of MDA-MB-231. * p<0.05; ** p<0.01; *** 
p<0.001 in the treatment group compared to the vehicle. 
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Fig. 3c and d. Apoptosis assay: (C) and (D) are respectively PC3 and U2OS quantitative 
representation. * p<0.05; ** p<0.01; *** p<0.001 in the treatment group compared to the 
vehicle. 
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Fig. 4a. MDA-MB-231 were cultured in 6-well plates until cnfluency (2 to 3 days), and then 
treated with the vehicle or 5 µM of BEA or ENN in starvation medium for 2, 6, 12 and 24 h. 
Following treatment, the cells were lysed, proteins separated by SDS-Electrophoresis and the 
western blot carried out to determine phosphorylation of proteins. All experiments were carried 
out at least in triplicate and representative radiographs are shown. 
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Fig. 4b. PC3 were cultured in 6-well plates until cnfluency (2 to 3 days), and then treated with 
the vehicle or 5 µM of BEA or ENN in starvation medium for 2, 6, 12 and 24 h. Following 
treatment, the cells were lysed, proteins separated by SDS-Electrophoresis and the western blot 
carried out to determine phosphorylation of proteins. All experiments were carried out at least in 
triplicate and representative radiographs are shown. 
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Fig. 4c. U2OS were cultured in 6-well plates until cnfluency (2 to 3 days), and then treated with 
the vehicle or 5 µM of BEA or ENN in starvation medium for 2, 6, 12 and 24 h. Following 
treatment, the cells were lysed, proteins separated by SDS-Electrophoresis and the western blot 
carried out to determine phosphorylation of proteins. All experiments were carried out at least in 
triplicate and representative radiographs are shown. 
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BEA and ENN are two secondary metabolites produced by several strains of the fungi 
genus Fusarium, Beauveria, Polyporus and Paecilomyces that are known to 
contaminate food and feed. Both mycotoxins belong to a group of 
cyclohexadepsipeptides, and exert ionophoric, antibiotic, insecticidal, phytotoxic, 
anthelminthic and cytotoxic properties. Yet, dextruxins, related cycodepsipeptides, have 
been shown to inhibit bone resorption without affecting osteoclast differentiation and 
survival, raising the need of screening BEA and ENN for their antiresorptives effects. 
Thus, in a first approach, this study aimed to characterize pharmacological and 
toxicological activities of BEA and ENN on bone cells, namely osteoblasts (OB) and 
osteoclasts (OC). 
we: 1- cocultured murine bone marrow cells with primary calvarial OB to generate OC, 
2- assessed OC differentiation and viability using TRAP staining, 3- performed pit 
analyses of bovine bone slices, and 4- stained the cytoskeleton with phalloidin. BEA 
and ENN dose-dependently inhibited OC differentiation and bone resorption from bone 
marrow precursors. At concentrations equal to 1 µM, BEA affected both OC 
differentiation from bone marrow precursors and bone resorption while ENN affected 
only OC differentiation from bone marrow precursors, but not bone resorption per se. 
At concentrations equal and lower than 1 µM, BEA and ENN had no effect on OC 
differentiation from pre-fusion OC. At 1 µM, BEA affected bone resorption from pre-
fusion OC, but not OC differentiation while at the same concentration (1 µM), ENN had 
no effect both in bone resorption and OC differentiation from pre-fusion OC. 
Cytoskeleton staining of OC treated with BEA or ENN confirmed that BEA, likewise 
dextruxins, primarily affects bone resorption by disrupting the resorbing organelle (actin 
ring) of OC and later on due to the reduction of TRAP+ multinucleated cells, while 
ENN has no effect on the actin ring structure, and therefore affects bone resorption by 
directly reducing the number of TRAP multinucleated OC. 
BEA induced apoptosis in pre-fusion OC with fragmentation and/or condensation of 
nuclei, but did not affect the viability of mature OC. Interestingly, ENN treated-pre-
fusion OC presented no signs of apoptosis, but dose-dependently inhibited OC viability 
after 12 h. Both mycotoxins, particularly BEA, induced apoptosis and reduced cell 
viability in the monocyte-macrophage cell line RAW 264.7 compared to OB, suggesting 
an effect on OC precursors. 
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BEA and ENN both affected the MAPK and Akt pathways in RAW 264.7- derived OC. 
However, in coculture-derived OC, BEA acted as a Src activator, promoted a Src-
dependent activation of Akt, up-regulated the MAPK pathway independently of Src and 
down-regulated the NFκB pathway independently of Src. Additionally, ENN that 
behaves like a Src kinase inhibitor, up-regulated the MAPK pathway independently of 
MEK and finally down-regulated the NFκB pathway in a MEK-independent manner. 
In summary, the 2 mycotoxins BEA and ENN, although structurally related, 
differentially regulate OC life span. BEA specifically inhibits bone resorption and 
induces apoptosis in pre-fusion OC by a mechanism probably involving 
upregulation of ERK1/2 while ENN specifically inhibits OC viability in a Src/Akt 
dependent manner. Interestingly, the reference MAPK inhibitor PD98059 failed to 
prevent upregulation of ERK1/2 when applied before ENN and thus, further 
analyses are necessary to fully characterize the origin of this upregulation of 
ERK1/2 in ENN treated OC. Both cyclodepsipeptides could therefore be potential 
candidates for osteoporotic therapies where they could be used alone or in 
combination. 
The skeleton is one of the most common locations in the body to which cancer, 
particularly from breast, lung and prostate metastasizes. Bone metastases therefore 
constitute a common cause of morbidity and mortality in cancer patients and to date, the 
treatment is primary palliative. As bone resorption seems to be the main mechanism in 
the early phases of bone metastasis, and probably the main mechanism by which 
osteolysis, particularly from breast and prostate cancer patient progresses, an effect of 
BEA and ENN on OC is therefore likely to impact on the tumour cell itself in the local 
bone milieu. However, it was interesting to examine the direct effect of BEA and ENN 
on tumour cells that have the ability to metastasize to the bone. Therefore, we 
investigated the pharmacological and toxicological effects of BEA and ENN on 2 
highly tumorigenic, hormone-independent cell lines MDA-MB-231 and PC3, and on a 
non metastatic cell line U2OS with characteristics of primary tumor of bone. 
At lower concentrations (0.1 and 1 µM), ENN time dependently (24 to 48 h) and 
significantly (up to 50 % inhibition after 48 h treatment of PC3 with 1 µM ENN, 
p<0.001 vs. control) inhibited proliferation of metastatic cells (MDA-MB-231 and PC3) 
as compared to BEA. However, BEA exerted more cell growth inhibitory effect at 
higher concentration (10 µM) in all 3 cell lines compared to ENN. BEA and ENN 
similarly affected the metastatic and non metastatic cell viability, as early as 24 h, with 
a significant effect observed already with 5 µM drug (p<0.001 vs. control). Both 
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inhibitors more potently induced apoptosis after 24 h in metastatic cells as compared to 
non metastatic, with ENN being more apoptotic as compared to BEA. 
We analyzed the signal transduction pathways leading to proliferation, survival, 
apoptosis and motility. Interestingly, the metastatic profile of the cells did not seem to 
confer any selective advantage for the effects of our inhibitors at the molecular level. 
Indeed, while the p38 MAPK pathway remained continuously activated (from 6 to 24 h) 
in all cell lines, BEA and ENN inactivated ERK in MDA-MB-231 as opposed to its 
upregulation in PC3 and U2OS. Moreover, BEA was able to induce PARP cleavage in 
all cell lines, although ENN did so only in PC3 cells. Finally, the cell-cell adhesion 
molecule E-cadherin, whose loss of expression and/or activity has been implicated in 
the progression of metastasis, was upregulated in all cell lines following BEA or ENN 
treatment. 
To summarize, BEA and ENN affected cell viability and induced apoptosis more 
potently in metastatic cells (MDA-MB-231 and PC3) as compared to the non 
metastatic one (U2OS). Interestingly, the metastatic profile of the cells did not 
seem to confer any selective advantage for the effects of our inhibitors at the 
molecular level. While BEA more commonly interfered with the MAPK and the 
mitochondrial apoptotic pathways in all cell lines, ENN interacted predominantly 
with the MAPK signaling. These data support the antitumoral effects of BEA and 
ENN, and their therapeutic potential in the treatment of OC-induced bone loss, 
bone cancer and skeletal metastases. 
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